

1 A bill to be entitled
2 An act relating to controlled substances; amending s.
3 893.03, F.S.; scheduling Mitragynine and 7-
4 Hydroxymitragynine, constituents of Kratom, in a
5 schedule of controlled substances; scheduling isomers,
6 esters, ethers, salts, and salts of isomers, esters,
7 and ethers of Mitragynine and 7-Hydroxymitragynine in
8 a schedule of controlled substances; providing an
9 exception from scheduling for any drug product
10 approved by the United States Food and Drug
11 Administration which contains Mitragynine or 7-
12 Hydroxymitragynine; amending s. 893.13, F.S.;
13 providing a criminal penalty; reenacting s.
14 39.01(30)(a) and (g), F.S., relating to definitions
15 used in chapter 39, F.S., s. 316.193(5), F.S.,
16 relating to driving under the influence, s.
17 322.2616(2)(c), F.S., relating to suspension of driver
18 licenses, s. 327.35(5), F.S., relating to boating
19 under the influence, s. 440.102(11)(b), F.S., relating
20 to drug-free workplace programs, ss. 458.3265(1)(e)
21 and 459.0137(1)(e), F.S., relating to pain-management
22 clinics, s. 782.04(1)(a) and (4), F.S., relating to
23 murder, s. 787.06(2)(a), F.S., relating to human
24 trafficking, s. 817.563, F.S., relating to sale of
25 substance in lieu of a controlled substance, s.

26 | 831.31(1)(a) and (2), F.S., relating to counterfeit
 27 | controlled substance, s. 856.015(1)(c), F.S., relating
 28 | to open house parties, s. 893.02(4), F.S., relating to
 29 | definitions, ss. 893.035(2), (7)(a), and (8)(a) and
 30 | 893.0356(2)(a) and (5), F.S., relating to control of
 31 | new substances, s. 893.05(1), F.S., relating to
 32 | practitioners and persons administering controlled
 33 | substances in their absence, s. 893.12(2)(b), (c), and
 34 | (d), F.S., relating to contraband, seizure,
 35 | forfeiture, and sale, s. 893.13(1)(a), (c), (d), (e),
 36 | (f), and (h), (2)(a), (4)(b), (5)(b), and (7)(a),
 37 | F.S., relating to prohibited acts and penalties, and
 38 | 921.0022(3)(b), (c), and (e), F.S., relating to the
 39 | offense severity ranking chart of the Criminal
 40 | Punishment Code, to incorporate the amendment made by
 41 | the act to s. 893.03, F.S., in references thereto;
 42 | providing an effective date.

43 |
 44 | Be It Enacted by the Legislature of the State of Florida:

45 |
 46 | Section 1. Paragraph (c) of subsection (1) of section
 47 | 893.03, Florida Statutes, is amended to read:

48 | 893.03 Standards and schedules.—The substances enumerated
 49 | in this section are controlled by this chapter. The controlled
 50 | substances listed or to be listed in Schedules I, II, III, IV,

51 and V are included by whatever official, common, usual,
52 chemical, trade name, or class designated. The provisions of
53 this section shall not be construed to include within any of the
54 schedules contained in this section any excluded drugs listed
55 within the purview of 21 C.F.R. s. 1308.22, styled "Excluded
56 Substances"; 21 C.F.R. s. 1308.24, styled "Exempt Chemical
57 Preparations"; 21 C.F.R. s. 1308.32, styled "Exempted
58 Prescription Products"; or 21 C.F.R. s. 1308.34, styled "Exempt
59 Anabolic Steroid Products."

60 (1) SCHEDULE I.—A substance in Schedule I has a high
61 potential for abuse and has no currently accepted medical use in
62 treatment in the United States and in its use under medical
63 supervision does not meet accepted safety standards. The
64 following substances are controlled in Schedule I:

65 (c) Unless specifically excepted or unless listed in
66 another schedule, any material, compound, mixture, or
67 preparation that contains any quantity of the following
68 hallucinogenic substances or that contains any of their salts,
69 isomers, including optical, positional, or geometric isomers,
70 homologues, nitrogen-heterocyclic analogs, esters, ethers, and
71 salts of isomers, homologues, nitrogen-heterocyclic analogs,
72 esters, or ethers, if the existence of such salts, isomers, and
73 salts of isomers is possible within the specific chemical
74 designation or class description:

75 1. Alpha-Ethyltryptamine.

- 76 | 2. 4-Methylaminorex (2-Amino-4-methyl-5-phenyl-2-
- 77 | oxazoline).
- 78 | 3. Aminorex (2-Amino-5-phenyl-2-oxazoline).
- 79 | 4. DOB (4-Bromo-2,5-dimethoxyamphetamine).
- 80 | 5. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
- 81 | 6. Bufotenine.
- 82 | 7. Cannabis.
- 83 | 8. Cathinone.
- 84 | 9. DET (Diethyltryptamine).
- 85 | 10. 2,5-Dimethoxyamphetamine.
- 86 | 11. DOET (4-Ethyl-2,5-Dimethoxyamphetamine).
- 87 | 12. DMT (Dimethyltryptamine).
- 88 | 13. PCE (N-Ethyl-1-phenylcyclohexylamine) (Ethylamine
- 89 | analog of phencyclidine).
- 90 | 14. JB-318 (N-Ethyl-3-piperidyl benzilate).
- 91 | 15. N-Ethylamphetamine.
- 92 | 16. Fenethylamine.
- 93 | 17. 3,4-Methylenedioxy-N-hydroxyamphetamine.
- 94 | 18. Ibogaine.
- 95 | 19. LSD (Lysergic acid diethylamide).
- 96 | 20. Mescaline.
- 97 | 21. Methcathinone.
- 98 | 22. 5-Methoxy-3,4-methylenedioxyamphetamine.
- 99 | 23. PMA (4-Methoxyamphetamine).
- 100 | 24. PMMA (4-Methoxymethamphetamine).

- 101 25. DOM (4-Methyl-2,5-dimethoxyamphetamine).
- 102 26. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
- 103 27. MDA (3,4-Methylenedioxyamphetamine).
- 104 28. JB-336 (N-Methyl-3-piperidyl benzilate).
- 105 29. N,N-Dimethylamphetamine.
- 106 30. Parahexyl.
- 107 31. Peyote.
- 108 32. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine
- 109 analog of phencyclidine).
- 110 33. Psilocybin.
- 111 34. Psilocyn.
- 112 35. Salvia divinorum, except for any drug product approved
- 113 by the United States Food and Drug Administration which contains
- 114 Salvia divinorum or its isomers, esters, ethers, salts, and
- 115 salts of isomers, esters, and ethers, if the existence of such
- 116 isomers, esters, ethers, and salts is possible within the
- 117 specific chemical designation.
- 118 36. Salvinorin A, except for any drug product approved by
- 119 the United States Food and Drug Administration which contains
- 120 Salvinorin A or its isomers, esters, ethers, salts, and salts of
- 121 isomers, esters, and ethers, if the existence of such isomers,
- 122 esters, ethers, and salts is possible within the specific
- 123 chemical designation.
- 124 37. Xylazine.
- 125 38. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)

- 126 | (Thiophene analog of phencyclidine).
 127 | 39. 3,4,5-Trimethoxyamphetamine.
 128 | 40. Methytlone (3,4-Methylenedioxyethcathinone).
 129 | 41. MDPV (3,4-Methylenedioxypropylvalerone).
 130 | 42. Methylnethcathinone.
 131 | 43. Methoxyethcathinone.
 132 | 44. Fluoromethcathinone.
 133 | 45. Methylethcathinone.
 134 | 46. CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2-
 135 | yl)phenol) and its dimethyloctyl (C8) homologue.
 136 | 47. HU-210 [(6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-
 137 | (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-
 138 | ol].
 139 | 48. JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
 140 | 49. JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
 141 | 50. JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-
 142 | naphthoyl)indole).
 143 | 51. BZP (Benzylpiperazine).
 144 | 52. Fluorophenylpiperazine.
 145 | 53. Methylphenylpiperazine.
 146 | 54. Chlorophenylpiperazine.
 147 | 55. Methoxyphenylpiperazine.
 148 | 56. DBZP (1,4-Dibenzylpiperazine).
 149 | 57. TFMPP (Trifluoromethylphenylpiperazine).
 150 | 58. MBDB (Methylbenzodioxolylbutanamine) or (3,4-

- 151 Methylendioxy-N-methylbutanamine).
- 152 59. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
- 153 60. 5-Hydroxy-N-methyltryptamine.
- 154 61. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
- 155 62. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
- 156 63. Methyltryptamine.
- 157 64. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
- 158 65. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
- 159 66. Tyramine (4-Hydroxyphenethylamine).
- 160 67. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
- 161 68. DiPT (N,N-Diisopropyltryptamine).
- 162 69. DPT (N,N-Dipropyltryptamine).
- 163 70. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
- 164 71. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
- 165 72. DOI (4-Iodo-2,5-dimethoxyamphetamine).
- 166 73. DOC (4-Chloro-2,5-dimethoxyamphetamine).
- 167 74. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
- 168 75. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
- 169 76. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
- 170 77. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
- 171 78. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
- 172 79. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
- 173 80. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
- 174 81. Butylone (3,4-Methylenedioxy-alpha-
- 175 methylaminobutyrophenone).

- 176 | 82. Ethcathinone.
- 177 | 83. Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
- 178 | 84. Naphyrone (Naphthylpyrovalerone).
- 179 | 85. Dimethylone (3,4-Methylenedioxy-N,N-
- 180 | dimethylcathinone).
- 181 | 86. 3,4-Methylenedioxy-N,N-diethylcathinone.
- 182 | 87. 3,4-Methylenedioxy-propiofenone.
- 183 | 88. 3,4-Methylenedioxy-alpha-bromopropiofenone.
- 184 | 89. 3,4-Methylenedioxy-propiofenone-2-oxime.
- 185 | 90. 3,4-Methylenedioxy-N-acetylcathinone.
- 186 | 91. 3,4-Methylenedioxy-N-acetylmethcathinone.
- 187 | 92. 3,4-Methylenedioxy-N-acetylcathinone.
- 188 | 93. Bromomethcathinone.
- 189 | 94. Buphedrone (alpha-Methylamino-butyrophenone).
- 190 | 95. Eutylone (3,4-Methylenedioxy-alpha-
- 191 | ethylaminobutyrophenone).
- 192 | 96. Dimethylcathinone.
- 193 | 97. Dimethylmethcathinone.
- 194 | 98. Pentylone (3,4-Methylenedioxy-alpha-
- 195 | methylaminovalerophenone).
- 196 | 99. MDPPP (3,4-Methylenedioxy-alpha-
- 197 | pyrrolidinopropiofenone).
- 198 | 100. MDPBP (3,4-Methylenedioxy-alpha-
- 199 | pyrrolidinobutyrophenone).
- 200 | 101. MOPPP (Methoxy-alpha-pyrrolidinopropiofenone).

- 201 102. MPHP (Methyl-alpha-pyrrolidinohexanophenone).
 202 103. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
 203 (Benocyclidine).
 204 104. F-MABP (Fluoromethylaminobutyrophenone).
 205 105. MeO-PBP (Methoxypyrrolidinobutyrophenone).
 206 106. Et-PBP (Ethylpyrrolidinobutyrophenone).
 207 107. 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
 208 108. Me-EABP (Methylethylaminobutyrophenone).
 209 109. Etizolam.
 210 110. PPP (Pyrrolidinopropiophenone).
 211 111. PBP (Pyrrolidinobutyrophenone).
 212 112. PVP (Pyrrolidinovalerophenone) or
 213 (Pyrrolidinopentiophenone).
 214 113. MPPP (Methyl-alpha-pyrrolidinopropiophenone).
 215 114. JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).
 216 115. JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).
 217 116. JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
 218 117. JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
 219 118. JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
 220 119. JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
 221 120. JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
 222 121. JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-
 223 methylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
 224 122. JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).
 225 123. JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).

- 226 | 124. JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl) indole).
 227 | 125. JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl) indole).
 228 | 126. JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole).
 229 | 127. JWH-251 (1-Pentyl-3-(2-methylphenylacetyl) indole).
 230 | 128. JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl) indole).
 231 | 129. JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl) indole).
 232 | 130. HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-
 233 | (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-
 234 | ol).
 235 | 131. HU-308 ([(1R,2R,5R)-2-[2,6-Dimethoxy-4-(2-
 236 | methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-
 237 | enyl] methanol).
 238 | 132. HU-331 (3-Hydroxy-2-[(1R,6R)-3-methyl-6-(1-
 239 | methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-
 240 | 1,4-dione).
 241 | 133. CB-13 (4-Pentyloxy-1-(1-naphthoyl) naphthalene).
 242 | 134. CB-25 (N-Cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)-
 243 | undecanamide).
 244 | 135. CB-52 (N-Cyclopropyl-11-(2-hexyl-5-hydroxyphenoxy)-
 245 | undecanamide).
 246 | 136. CP 55,940 (2-[3-Hydroxy-6-propanol-cyclohexyl]-5-(2-
 247 | methyloctan-2-yl)phenol).
 248 | 137. AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl) indole).
 249 | 138. AM-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl) indole).
 250 | 139. RCS-4 (1-Pentyl-3-(4-methoxybenzoyl) indole).

- 251 140. RCS-8 (1-(2-Cyclohexylethyl)-3-(2-
252 methoxyphenylacetyl) indole).
- 253 141. WIN55,212-2 ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4-
254 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-
255 naphthalenylmethanone).
- 256 142. WIN55,212-3 ([(3S)-2,3-Dihydro-5-methyl-3-(4-
257 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-
258 naphthalenylmethanone).
- 259 143. Pentedrone (alpha-Methylaminovalerophenone).
- 260 144. Fluoroamphetamine.
- 261 145. Fluoromethamphetamine.
- 262 146. Methoxetamine.
- 263 147. Methiopropamine.
- 264 148. Methylbuphedrone (Methyl-alpha-
265 methylaminobutyrophenone).
- 266 149. APB ((2-Aminopropyl)benzofuran).
- 267 150. APDB ((2-Aminopropyl)-2,3-dihydrobenzofuran).
- 268 151. UR-144 (1-Pentyl-3-(2,2,3,3-
269 tetramethylcyclopropanoyl) indole).
- 270 152. XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3-
271 tetramethylcyclopropanoyl) indole).
- 272 153. Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3-
273 tetramethylcyclopropanoyl) indole).
- 274 154. AKB48 (N-Adamant-1-yl 1-pentylindazole-3-
275 carboxamide).

- 276 | 155. AM-2233 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-
 277 | iodobenzoyl) indole) .
- 278 | 156. STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl) indole-3-
 279 | carboxamide) .
- 280 | 157. URB-597 ((3'-(Aminocarbonyl) [1,1'-biphenyl]-3-yl)-
 281 | cyclohexylcarbamate) .
- 282 | 158. URB-602 ([1,1'-Biphenyl]-3-yl-carbamic acid,
 283 | cyclohexyl ester) .
- 284 | 159. URB-754 (6-Methyl-2-[(4-methylphenyl) amino]-1-
 285 | benzoxazin-4-one) .
- 286 | 160. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine) .
- 287 | 161. 2C-H (2,5-Dimethoxyphenethylamine) .
- 288 | 162. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine) .
- 289 | 163. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine) .
- 290 | 164. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2-
 291 | methoxybenzyl)]phenethylamine) .
- 292 | 165. MDMA (3,4-Methylenedioxyamphetamine) .
- 293 | 166. PB-22 (8-Quinolinyll 1-pentylindole-3-carboxylate) .
- 294 | 167. Fluoro PB-22 (8-Quinolinyll 1-(fluoropentyl) indole-3-
 295 | carboxylate) .
- 296 | 168. BB-22 (8-Quinolinyll 1-(cyclohexylmethyl) indole-3-
 297 | carboxylate) .
- 298 | 169. Fluoro AKB48 (N-Adamant-1-yl 1-
 299 | (fluoropentyl) indazole-3-carboxamide) .
- 300 | 170. AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-

301 penty lindazole-3-carboxamide).

302 171. AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-

303 (4-fluorobenzyl)indazole-3-carboxamide).

304 172. ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-

305 1-penty lindazole-3-carboxamide).

306 173. Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-

307 yl)-1-(fluoropentyl)indole-3-carboxamide).

308 174. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2-

309 methoxybenzyl)]phenethylamine).

310 175. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2-

311 methoxybenzyl)]phenethylamine).

312 176. AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-

313 (cyclohexylmethyl)indazole-3-carboxamide).

314 177. FUB-PB-22 (8-Quinoliny l 1-(4-fluorobenzyl)indole-3-

315 carboxylate).

316 178. Fluoro-NNEI (N-Naphthalen-1-yl 1-

317 (fluoropentyl)indole-3-carboxamide).

318 179. Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-

319 (fluoropentyl)indazole-3-carboxamide).

320 180. THJ-2201 (1-(5-Fluoropentyl)-3-(1-

321 naphthoyl)indazole).

322 181. AM-855 ((4aR,12bR)-8-Hexyl-2,5,5-trimethyl-

323 1,4,4a,8,9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol).

324 182. AM-905 ((6aR,9R,10aR)-3-[(E)-Hept-1-enyl]-9-

325 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-

326 hexahydrobenzo[c]chromen-1-ol).

327 183. AM-906 ((6aR,9R,10aR)-3-[(Z)-Hept-1-enyl]-9-

328 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-

329 hexahydrobenzo[c]chromen-1-ol).

330 184. AM-2389 ((6aR,9R,10aR)-3-(1-Hexyl-cyclobut-1-yl)-

331 6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9

332 diol).

333 185. HU-243 ((6aR,8S,9S,10aR)-9-(Hydroxymethyl)-6,6-

334 dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a-

335 tetrahydro-6aH-benzo[c]chromen-1-ol).

336 186. HU-336 ((6aR,10aR)-6,6,9-Trimethyl-3-pentyl-

337 6a,7,10,10a-tetrahydro-1H-benzo[c]chromene-1,4(6H)-dione).

338 187. MAPB ((2-Methylaminopropyl)benzofuran).

339 188. 5-IT (2-(1H-Indol-5-yl)-1-methyl-ethylamine).

340 189. 6-IT (2-(1H-Indol-6-yl)-1-methyl-ethylamine).

341 190. Synthetic Cannabinoids.—Unless specifically excepted

342 or unless listed in another schedule or contained within a

343 pharmaceutical product approved by the United States Food and

344 Drug Administration, any material, compound, mixture, or

345 preparation that contains any quantity of a synthetic

346 cannabinoid found to be in any of the following chemical class

347 descriptions, or homologues, nitrogen-heterocyclic analogs,

348 isomers (including optical, positional, or geometric), esters,

349 ethers, salts, and salts of homologues, nitrogen-heterocyclic

350 analogs, isomers, esters, or ethers, whenever the existence of

351 such homologues, nitrogen-heterocyclic analogs, isomers, esters,
352 ethers, salts, and salts of isomers, esters, or ethers is
353 possible within the specific chemical class or designation.

354 Since nomenclature of these synthetically produced cannabinoids
355 is not internationally standardized and may continually evolve,
356 these structures or the compounds of these structures shall be
357 included under this subparagraph, regardless of their specific
358 numerical designation of atomic positions covered, if it can be
359 determined through a recognized method of scientific testing or
360 analysis that the substance contains properties that fit within
361 one or more of the following categories:

362 a. Tetrahydrocannabinols.—Any tetrahydrocannabinols
363 naturally contained in a plant of the genus Cannabis, the
364 synthetic equivalents of the substances contained in the plant
365 or in the resinous extracts of the genus Cannabis, or synthetic
366 substances, derivatives, and their isomers with similar chemical
367 structure and pharmacological activity, including, but not
368 limited to, Delta 9 tetrahydrocannabinols and their optical
369 isomers, Delta 8 tetrahydrocannabinols and their optical
370 isomers, Delta 6a,10a tetrahydrocannabinols and their optical
371 isomers, or any compound containing a tetrahydrobenzo[c]chromene
372 structure with substitution at either or both the 3-position or
373 9-position, with or without substitution at the 1-position with
374 hydroxyl or alkoxy groups, including, but not limited to:

375 (I) Tetrahydrocannabinol.

376 (II) HU-210 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-
377 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-
378 ol).

379 (III) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-
380 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-
381 ol).

382 (IV) JWH-051 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-
383 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).

384 (V) JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan-
385 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).

386 (VI) JWH-057 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methyloctan-
387 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).

388 (VII) JWH-359 ((6aR,10aR)-1-Methoxy-6,6,9-trimethyl-3-
389 (2,3-dimethylpentan-2-yl)-6a,7,10,10a-
390 tetrahydrobenzo[c]chromene).

391 (VIII) AM-087 ((6aR,10aR)-3-(2-Methyl-6-bromohex-2-yl)-
392 6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).

393 (IX) AM-411 ((6aR,10aR)-3-(1-Adamantyl)-6,6,9-trimethyl-
394 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).

395 (X) Parahexyl.

396 b. Naphthoylindoles, Naphthoylindazoles,
397 Naphthoylcarbazoles, Naphthylmethylindoles,
398 Naphthylmethylindazoles, and Naphthylmethylcarbazoles.—Any
399 compound containing a naphthoylindole, naphthoylindazole,
400 naphthoylcarbazole, naphthylmethylindole,

401 naphthylmethylindazole, or naphthylmethylcarbazole structure,
402 with or without substitution on the indole, indazole, or
403 carbazole ring to any extent, whether or not substituted on the
404 naphthyl ring to any extent, including, but not limited to:

405 (I) JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).
406 (II) JWH-011 (1-(1-Methylhexyl)-2-methyl-3-(1-
407 naphthoyl)indole).
408 (III) JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).
409 (IV) JWH-016 (1-Butyl-2-methyl-3-(1-naphthoyl)indole).
410 (V) JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
411 (VI) JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
412 (VII) JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
413 (VIII) JWH-022 (1-(4-Pentenyl)-3-(1-naphthoyl)indole).
414 (IX) JWH-071 (1-Ethyl-3-(1-naphthoyl)indole).
415 (X) JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
416 (XI) JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
417 (XII) JWH-080 (1-Butyl-3-(4-methoxy-1-naphthoyl)indole).
418 (XIII) JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
419 (XIV) JWH-098 (1-Pentyl-2-methyl-3-(4-methoxy-1-
420 naphthoyl)indole).
421 (XV) JWH-116 (1-Pentyl-2-ethyl-3-(1-naphthoyl)indole).
422 (XVI) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
423 (XVII) JWH-149 (1-Pentyl-2-methyl-3-(4-methyl-1-
424 naphthoyl)indole).
425 (XVIII) JWH-164 (1-Pentyl-3-(7-methoxy-1-

426 naphthoyl) indole).

427 (XIX) JWH-175 (1-Pentyl-3-(1-naphthylmethyl) indole).

428 (XX) JWH-180 (1-Propyl-3-(4-propyl-1-naphthoyl) indole).

429 (XXI) JWH-182 (1-Pentyl-3-(4-propyl-1-naphthoyl) indole).

430 (XXII) JWH-184 (1-Pentyl-3-[(4-methyl)-1-

431 naphthylmethyl] indole).

432 (XXIII) JWH-193 (1-[2-(4-Morpholinyl) ethyl]-3-(4-methyl-1-

433 naphthoyl) indole).

434 (XXIV) JWH-198 (1-[2-(4-Morpholinyl) ethyl]-3-(4-methoxy-1-

435 naphthoyl) indole).

436 (XXV) JWH-200 (1-[2-(4-Morpholinyl) ethyl]-3-(1-

437 naphthoyl) indole).

438 (XXVI) JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl) indole).

439 (XXVII) JWH-387 (1-Pentyl-3-(4-bromo-1-naphthoyl) indole).

440 (XXVIII) JWH-398 (1-Pentyl-3-(4-chloro-1-

441 naphthoyl) indole).

442 (XXIX) JWH-412 (1-Pentyl-3-(4-fluoro-1-naphthoyl) indole).

443 (XXX) JWH-424 (1-Pentyl-3-(8-bromo-1-naphthoyl) indole).

444 (XXXI) AM-1220 (1-[(1-Methyl-2-piperidinyl) methyl]-3-(1-

445 naphthoyl) indole).

446 (XXXII) AM-1235 (1-(5-Fluoropentyl)-6-nitro-3-(1-

447 naphthoyl) indole).

448 (XXXIII) AM-2201 (1-(5-Fluoropentyl)-3-(1-

449 naphthoyl) indole).

450 (XXXIV) Chloro JWH-018 (1-(Chloropentyl)-3-(1-

451 naphthoyl) indole).

452 (XXXV) Bromo JWH-018 (1-(Bromopentyl)-3-(1-

453 naphthoyl) indole).

454 (XXXVI) AM-2232 (1-(4-Cyanobutyl)-3-(1-naphthoyl) indole).

455 (XXXVII) THJ-2201 (1-(5-Fluoropentyl)-3-(1-

456 naphthoyl) indazole).

457 (XXXVIII) MAM-2201 (1-(5-Fluoropentyl)-3-(4-methyl-1-

458 naphthoyl) indole).

459 (XXXIX) EAM-2201 (1-(5-Fluoropentyl)-3-(4-ethyl-1-

460 naphthoyl) indole).

461 (XL) EG-018 (9-Pentyl-3-(1-naphthoyl) carbazole).

462 (XLI) EG-2201 (9-(5-Fluoropentyl)-3-(1-

463 naphthoyl) carbazole).

464 c. Naphthoylpyrroles.—Any compound containing a

465 naphthoylpyrrole structure, with or without substitution on the

466 pyrrole ring to any extent, whether or not substituted on the

467 naphthyl ring to any extent, including, but not limited to:

468 (I) JWH-030 (1-Pentyl-3-(1-naphthoyl) pyrrole).

469 (II) JWH-031 (1-Hexyl-3-(1-naphthoyl) pyrrole).

470 (III) JWH-145 (1-Pentyl-5-phenyl-3-(1-naphthoyl) pyrrole).

471 (IV) JWH-146 (1-Heptyl-5-phenyl-3-(1-naphthoyl) pyrrole).

472 (V) JWH-147 (1-Hexyl-5-phenyl-3-(1-naphthoyl) pyrrole).

473 (VI) JWH-307 (1-Pentyl-5-(2-fluorophenyl)-3-(1-

474 naphthoyl) pyrrole).

475 (VII) JWH-309 (1-Pentyl-5-(1-naphthalenyl)-3-(1-

476 naphthoyl)pyrrole).

477 (VIII) JWH-368 (1-Pentyl-5-(3-fluorophenyl)-3-(1-
478 naphthoyl)pyrrole).

479 (IX) JWH-369 (1-Pentyl-5-(2-chlorophenyl)-3-(1-
480 naphthoyl)pyrrole).

481 (X) JWH-370 (1-Pentyl-5-(2-methylphenyl)-3-(1-
482 naphthoyl)pyrrole).

483 d. Naphthylmethylenindenes.—Any compound containing a
484 naphthylmethylenindene structure, with or without substitution
485 at the 3-position of the indene ring to any extent, whether or
486 not substituted on the naphthyl ring to any extent, including,
487 but not limited to, JWH-176 (3-Pentyl-1-
488 (naphthylmethylene)indene).

489 e. Phenylacetylindoles and Phenylacetylindazoles.—Any
490 compound containing a phenylacetylindole or phenylacetylindazole
491 structure, with or without substitution on the indole or
492 indazole ring to any extent, whether or not substituted on the
493 phenyl ring to any extent, including, but not limited to:

494 (I) JWH-167 (1-Pentyl-3-(phenylacetyl)indole).

495 (II) JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).

496 (III) JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).

497 (IV) JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).

498 (V) JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).

499 (VI) JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).

500 (VII) Cannabipiperidiethanone.

501 (VIII) RCS-8 (1-(2-Cyclohexylethyl)-3-(2-
502 methoxyphenylacetyl)indole).

503 f. Cyclohexylphenols.—Any compound containing a
504 cyclohexylphenol structure, with or without substitution at the
505 5-position of the phenolic ring to any extent, whether or not
506 substituted on the cyclohexyl ring to any extent, including, but
507 not limited to:

508 (I) CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2-
509 yl)phenol).

510 (II) Cannabicyclohexanol (CP 47,497 dimethyloctyl (C8)
511 homologue).

512 (III) CP-55,940 (2-(3-Hydroxy-6-propanol-cyclohexyl)-5-(2-
513 methyloctan-2-yl)phenol).

514 g. Benzoylindoles and Benzoylindazoles.—Any compound
515 containing a benzoylindole or benzoylindazole structure, with or
516 without substitution on the indole or indazole ring to any
517 extent, whether or not substituted on the phenyl ring to any
518 extent, including, but not limited to:

519 (I) AM-679 (1-Pentyl-3-(2-iodobenzoyl)indole).

520 (II) AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).

521 (III) AM-1241 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-
522 iodo-5-nitrobenzoyl)indole).

523 (IV) Pravadoline (1-[2-(4-Morpholinyl)ethyl]-2-methyl-3-
524 (4-methoxybenzoyl)indole).

525 (V) AM-2233 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-

526 iodobenzoyl) indole).

527 (VI) RCS-4 (1-Pentyl-3-(4-methoxybenzoyl) indole).

528 (VII) RCS-4 C4 homologue (1-Butyl-3-(4-

529 methoxybenzoyl) indole).

530 (VIII) AM-630 (1-[2-(4-Morpholinyl)ethyl]-2-methyl-6-iodo-

531 3-(4-methoxybenzoyl) indole).

532 h. Tetramethylcyclopropanoylindoles and

533 Tetramethylcyclopropanoylindazoles.—Any compound containing a

534 tetramethylcyclopropanoylindole or

535 tetramethylcyclopropanoylindazole structure, with or without

536 substitution on the indole or indazole ring to any extent,

537 whether or not substituted on the tetramethylcyclopropyl group

538 to any extent, including, but not limited to:

539 (I) UR-144 (1-Pentyl-3-(2,2,3,3-

540 tetramethylcyclopropanoyl) indole).

541 (II) XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3-

542 tetramethylcyclopropanoyl) indole).

543 (III) Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3-

544 tetramethylcyclopropanoyl) indole).

545 (IV) A-796,260 (1-[2-(4-Morpholinyl)ethyl]-3-(2,2,3,3-

546 tetramethylcyclopropanoyl) indole).

547 (V) A-834,735 (1-[4-(Tetrahydropyranyl)methyl]-3-(2,2,3,3-

548 tetramethylcyclopropanoyl) indole).

549 (VI) M-144 (1-(5-Fluoropentyl)-2-methyl-3-(2,2,3,3-

550 tetramethylcyclopropanoyl) indole).

- 551 (VII) FUB-144 (1-(4-Fluorobenzyl)-3-(2,2,3,3-
 552 tetramethylcyclopropanoyl)indole).
- 553 (VIII) FAB-144 (1-(5-Fluoropentyl)-3-(2,2,3,3-
 554 tetramethylcyclopropanoyl)indazole).
- 555 (IX) XLR12 (1-(4,4,4-Trifluorobutyl)-3-(2,2,3,3-
 556 tetramethylcyclopropanoyl)indole).
- 557 (X) AB-005 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(2,2,3,3-
 558 tetramethylcyclopropanoyl)indole).
- 559 i. Adamantoylindoles, Adamantoylindazoles, Adamantylindole
 560 carboxamides, and Adamantylindazole carboxamides.—Any compound
 561 containing an adamantoyl indole, adamantoyl indazole, adamantyl
 562 indole carboxamide, or adamantyl indazole carboxamide structure,
 563 with or without substitution on the indole or indazole ring to
 564 any extent, whether or not substituted on the adamantyl ring to
 565 any extent, including, but not limited to:
- 566 (I) AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).
- 567 (II) Fluoro AKB48 (N-Adamant-1-yl 1-
 568 (fluoropentyl)indazole-3-carboxamide).
- 569 (III) STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3-
 570 carboxamide).
- 571 (IV) AM-1248 (1-(1-Methylpiperidine)methyl-3-(1-
 572 adamantoyl)indole).
- 573 (V) AB-001 (1-Pentyl-3-(1-adamantoyl)indole).
- 574 (VI) APICA (N-Adamant-1-yl 1-pentylindole-3-carboxamide).
- 575 (VII) Fluoro AB-001 (1-(Fluoropentyl)-3-(1-

576 adamantoyl)indole).

577 j. Quinolinyndolecarboxylates,
578 Quinolinyndazolecarboxylates, Quinolinyndolecarboxamides,
579 and Quinolinyndazolecarboxamides.—Any compound containing a
580 quinolinyndole carboxylate, quinolinyndazole carboxylate,
581 isoquinolinyndole carboxylate, isoquinolinyndazole
582 carboxylate, quinolinyndole carboxamide, quinolinyndazole
583 carboxamide, isoquinolinyndole carboxamide, or
584 isoquinolinyndazole carboxamide structure, with or without
585 substitution on the indole or indazole ring to any extent,
586 whether or not substituted on the quinoline or isoquinoline ring
587 to any extent, including, but not limited to:

588 (I) PB-22 (8-Quinolinyndyl 1-pentyndole-3-carboxylate).

589 (II) Fluoro PB-22 (8-Quinolinyndyl 1-(fluoropentynd)indole-3-
590 carboxylate).

591 (III) BB-22 (8-Quinolinyndyl 1-(cyclohexyndmethyl)indole-3-
592 carboxylate).

593 (IV) FUB-PB-22 (8-Quinolinyndyl 1-(4-fluorobenzyl)indole-3-
594 carboxylate).

595 (V) NPB-22 (8-Quinolinyndyl 1-pentyndazole-3-carboxylate).

596 (VI) Fluoro NPB-22 (8-Quinolinyndyl 1-(fluoropentynd)indazole-
597 3-carboxylate).

598 (VII) FUB-NPB-22 (8-Quinolinyndyl 1-(4-fluorobenzyl)indazole-
599 3-carboxylate).

600 (VIII) THJ (8-Quinolinyndyl 1-pentyndazole-3-carboxamide).

601 (IX) Fluoro THJ (8-Quinoliny 1-(fluoropentyl)indazole-3-
602 carboxamide).

603 k. Naphthylindolecarboxylates and
604 Naphthylindazolecarboxylates.—Any compound containing a
605 naphthylindole carboxylate or naphthylindazole carboxylate
606 structure, with or without substitution on the indole or
607 indazole ring to any extent, whether or not substituted on the
608 naphthyl ring to any extent, including, but not limited to:

609 (I) NM-2201 (1-Naphthalenyl 1-(5-fluoropentyl)indole-3-
610 carboxylate).

611 (II) SDB-005 (1-Naphthalenyl 1-pentylindazole-3-
612 carboxylate).

613 (III) Fluoro SDB-005 (1-Naphthalenyl 1-
614 (fluoropentyl)indazole-3-carboxylate).

615 (IV) FDU-PB-22 (1-Naphthalenyl 1-(4-fluorobenzyl)indole-3-
616 carboxylate).

617 (V) 3-CAF (2-Naphthalenyl 1-(2-fluorophenyl)indazole-3-
618 carboxylate).

619 l. Naphthylindole carboxamides and Naphthylindazole
620 carboxamides.—Any compound containing a naphthylindole
621 carboxamide or naphthylindazole carboxamide structure, with or
622 without substitution on the indole or indazole ring to any
623 extent, whether or not substituted on the naphthyl ring to any
624 extent, including, but not limited to:

625 (I) NNEI (N-Naphthalen-1-yl 1-pentylindole-3-carboxamide).

626 (II) Fluoro-NNEI (N-Naphthalen-1-yl 1-
627 (fluoropentyl)indole-3-carboxamide).

628 (III) Chloro-NNEI (N-Naphthalen-1-yl 1-
629 (chloropentyl)indole-3-carboxamide).

630 (IV) MN-18 (N-Naphthalen-1-yl 1-pentylindazole-3-
631 carboxamide).

632 (V) Fluoro MN-18 (N-Naphthalen-1-yl 1-
633 (fluoropentyl)indazole-3-carboxamide).

634 m. Alkylcarbonyl indole carboxamides, Alkylcarbonyl
635 indazole carboxamides, Alkylcarbonyl indole carboxylates, and
636 Alkylcarbonyl indazole carboxylates.—Any compound containing an
637 alkylcarbonyl group, including 1-amino-3-methyl-1-oxobutan-2-yl,
638 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-amino-1-oxo-3-
639 phenylpropan-2-yl, 1-methoxy-1-oxo-3-phenylpropan-2-yl, with an
640 indole carboxamide, indazole carboxamide, indole carboxylate, or
641 indazole carboxylate, with or without substitution on the indole
642 or indazole ring to any extent, whether or not substituted on
643 the alkylcarbonyl group to any extent, including, but not
644 limited to:

645 (I) ADBICA, (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
646 pentylindole-3-carboxamide).

647 (II) Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-
648 yl)-1-(fluoropentyl)indole-3-carboxamide).

649 (III) Fluoro ABICA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-
650 1-(fluoropentyl)indole-3-carboxamide).

- 651 (IV) AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-
652 penty lindazole-3-carboxamide) .
- 653 (V) Fluoro AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-
654 yl)-1-(fluoropentyl) indazole-3-carboxamide) .
- 655 (VI) ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-
656 1-penty lindazole-3-carboxamide) .
- 657 (VII) Fluoro ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-
658 oxobutan-2-yl)-1-(fluoropentyl) indazole-3-carboxamide) .
- 659 (VIII) AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-
660 1-(4-fluorobenzyl) indazole-3-carboxamide) .
- 661 (IX) ADB-FUBINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-
662 yl)-1-(4-fluorobenzyl) indazole-3-carboxamide) .
- 663 (X) AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-
664 (cyclohexylmethyl) indazole-3-carboxamide) .
- 665 (XI) MA-CHMINACA (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-
666 1-(cyclohexylmethyl) indazole-3-carboxamide) .
- 667 (XII) MAB-CHMINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-
668 yl)-1-(cyclohexylmethyl) indazole-3-carboxamide) .
- 669 (XIII) AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-
670 penty lindazole-3-carboxamide) .
- 671 (XIV) Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-
672 1-(fluoropentyl) indazole-3-carboxamide) .
- 673 (XV) FUB-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-(4-
674 fluorobenzyl) indazole-3-carboxamide) .
- 675 (XVI) MDMB-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-

HB 183

2017

676 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).

677 (XVII) MDMB-FUBINACA (N-(1-Methoxy-3,3-dimethyl-1-

678 oxobutan-2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).

679 (XVIII) MDMB-CHMICA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-

680 2-yl)-1-(cyclohexylmethyl)indole-3-carboxamide).

681 (XIX) PX-1 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-

682 fluoropentyl)indole-3-carboxamide).

683 (XX) PX-2 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-

684 fluoropentyl)indazole-3-carboxamide).

685 (XXI) PX-3 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-

686 (cyclohexylmethyl)indazole-3-carboxamide).

687 (XXII) PX-4 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(4-

688 fluorobenzyl)indazole-3-carboxamide).

689 (XXIII) MO-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-

690 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxylate).

691 n. Cumylindolecarboxamides and Cumylindazolecarboxamides.—

692 Any compound containing a N-(2-phenylpropan-2-yl) indole

693 carboxamide or N-(2-phenylpropan-2-yl) indazole carboxamide

694 structure, with or without substitution on the indole or

695 indazole ring to any extent, whether or not substituted on the

696 phenyl ring of the cumyl group to any extent, including, but not

697 limited to:

698 (I) CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-pentylindole-3-

699 carboxamide).

700 (II) Fluoro CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-

701 (fluoropentyl)indole-3-carboxamide).

702 o. Other Synthetic Cannabinoids.—Any material, compound,
703 mixture, or preparation that contains any quantity of a
704 Synthetic Cannabinoid, as described in sub-subparagraphs a.-n.:

705 (I) With or without modification or replacement of a
706 carbonyl, carboxamide, alkylene, alkyl, or carboxylate linkage
707 between either two core rings, or linkage between a core ring
708 and group structure, with or without the addition of a carbon or
709 replacement of a carbon;

710 (II) With or without replacement of a core ring or group
711 structure, whether or not substituted on the ring or group
712 structures to any extent; and

713 (III) Is a cannabinoid receptor agonist, unless
714 specifically excepted or unless listed in another schedule or
715 contained within a pharmaceutical product approved by the United
716 States Food and Drug Administration.

717 191. Substituted Cathinones.—Unless specifically excepted,
718 listed in another schedule, or contained within a pharmaceutical
719 product approved by the United States Food and Drug
720 Administration, any material, compound, mixture, or preparation,
721 including its salts, isomers, esters, or ethers, and salts of
722 isomers, esters, or ethers, whenever the existence of such salts
723 is possible within any of the following specific chemical
724 designations:

725 a. Any compound containing a 2-amino-1-phenyl-1-propanone

726 structure;

727 b. Any compound containing a 2-amino-1-naphthyl-1-
728 propanone structure; or

729 c. Any compound containing a 2-amino-1-thiophenyl-1-
730 propanone structure,

731 whether or not the compound is further modified:

732 (I) With or without substitution on the ring system to any
733 extent with alkyl, alkylthio, thio, fused alkylenedioxy, alkoxy,
734 haloalkyl, hydroxyl, nitro, fused furan, fused benzofuran, fused
735 dihydrofuran, fused tetrahydropyran, fused alkyl ring, or halide
736 substituents;

737 (II) With or without substitution at the 3-propanone
738 position with an alkyl substituent or removal of the methyl
739 group at the 3-propanone position;

740 (III) With or without substitution at the 2-amino nitrogen
741 atom with alkyl, dialkyl, acetyl, or benzyl groups, whether or
742 not further substituted in the ring system; or

743 (IV) With or without inclusion of the 2-amino nitrogen
744 atom in a cyclic structure, including, but not limited to:

745 (A) Methcathinone.

746 (B) Ethcathinone.

747 (C) Methydone (3,4-Methylenedioxy-methcathinone).

748 (D) 2,3-Methylenedioxy-methcathinone.

749 (E) MDPV (3,4-Methylenedioxy-pyrovalerone).

750 (F) Methylmethcathinone.

- 751 (G) Methoxymethcathinone.
- 752 (H) Fluoromethcathinone.
- 753 (I) Methylethcathinone.
- 754 (J) Butylone (3,4-Methylenedioxy-alpha-
- 755 methylaminobutyrophenone).
- 756 (K) Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
- 757 (L) BMDP (3,4-Methylenedioxy-N-benzylcathinone).
- 758 (M) Naphyrone (Naphthylpyrovalerone).
- 759 (N) Bromomethcathinone.
- 760 (O) Buphedrone (alpha-Methylaminobutyrophenone).
- 761 (P) Eutylone (3,4-Methylenedioxy-alpha-
- 762 ethylaminobutyrophenone).
- 763 (Q) Dimethylcathinone.
- 764 (R) Dimethylmethcathinone.
- 765 (S) Pentylone (3,4-Methylenedioxy-alpha-
- 766 methylaminovalerophenone).
- 767 (T) Pentedrone (alpha-Methylaminovalerophenone).
- 768 (U) MDPPP (3,4-Methylenedioxy-alpha-
- 769 pyrrolidinopropiophenone).
- 770 (V) MDPBP (3,4-Methylenedioxy-alpha-
- 771 pyrrolidinobutyrophenone).
- 772 (W) MPPP (Methyl-alpha-pyrrolidinopropiophenone).
- 773 (X) PPP (Pyrrolidinopropiophenone).
- 774 (Y) PVP (Pyrrolidinovalerophenone) or
- 775 (Pyrrolidinopentiophenone).

- 776 (Z) MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
- 777 (AA) MPHP (Methyl-alpha-pyrrolidinohexanophenone).
- 778 (BB) F-MABP (Fluoromethylaminobutyrophenone).
- 779 (CC) Me-EABP (Methylethylaminobutyrophenone).
- 780 (DD) PBP (Pyrrolidinobutyrophenone).
- 781 (EE) MeO-PBP (Methoxypyrrolidinobutyrophenone).
- 782 (FF) Et-PBP (Ethylpyrrolidinobutyrophenone).
- 783 (GG) 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
- 784 (HH) Dimethylone (3,4-Methylenedioxy-N,N-
- 785 dimethylcathinone).
- 786 (II) 3,4-Methylenedioxy-N,N-diethylcathinone.
- 787 (JJ) 3,4-Methylenedioxy-N-acetylcathinone.
- 788 (KK) 3,4-Methylenedioxy-N-acetylmethcathinone.
- 789 (LL) 3,4-Methylenedioxy-N-acetylethcathinone.
- 790 (MM) Methylbuphedrone (Methyl-alpha-
- 791 methylaminobutyrophenone).
- 792 (NN) Methyl-alpha-methylaminohexanophenone.
- 793 (OO) N-Ethyl-N-methylcathinone.
- 794 (PP) PHP (Pyrrolidinohexanophenone).
- 795 (QQ) PV8 (Pyrrolidinoheptanophenone).
- 796 (RR) Chloromethcathinone.
- 797 (SS) 4-Bromo-2,5-dimethoxy-alpha-aminoacetophenone.
- 798 192. Substituted Phenethylamines.—Unless specifically
- 799 excepted or unless listed in another schedule, or contained
- 800 within a pharmaceutical product approved by the United States

801 Food and Drug Administration, any material, compound, mixture,
802 or preparation, including its salts, isomers, esters, or ethers,
803 and salts of isomers, esters, or ethers, whenever the existence
804 of such salts is possible within any of the following specific
805 chemical designations, any compound containing a phenethylamine
806 structure, without a beta-keto group, and without a benzyl group
807 attached to the amine group, whether or not the compound is
808 further modified with or without substitution on the phenyl ring
809 to any extent with alkyl, alkylthio, nitro, alkoxy, thio,
810 halide, fused alkylendioxy, fused furan, fused benzofuran,
811 fused dihydrofuran, or fused tetrahydropyran substituents,
812 whether or not further substituted on a ring to any extent, with
813 or without substitution at the alpha or beta position by any
814 alkyl substituent, with or without substitution at the nitrogen
815 atom, and with or without inclusion of the 2-amino nitrogen atom
816 in a cyclic structure, including, but not limited to:

- 817 a. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
- 818 b. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
- 819 c. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
- 820 d. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
- 821 e. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
- 822 f. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
- 823 g. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
- 824 h. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
- 825 i. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).

- 826 | j. 2C-H (2,5-Dimethoxyphenethylamine) .
- 827 | k. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine) .
- 828 | l. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine) .
- 829 | m. MDMA (3,4-Methylenedioxyamphetamine) .
- 830 | n. MBDB (Methylbenzodioxolylbutanamine) or (3,4-
- 831 | Methylene-dioxy-N-methylbutanamine) .
- 832 | o. MDA (3,4-Methylenedioxyamphetamine) .
- 833 | p. 2,5-Dimethoxyamphetamine .
- 834 | q. Fluoroamphetamine .
- 835 | r. Fluoromethamphetamine .
- 836 | s. MDEA (3,4-Methylenedioxy-N-ethylamphetamine) .
- 837 | t. DOB (4-Bromo-2,5-dimethoxyamphetamine) .
- 838 | u. DOC (4-Chloro-2,5-dimethoxyamphetamine) .
- 839 | v. DOET (4-Ethyl-2,5-dimethoxyamphetamine) .
- 840 | w. DOI (4-Iodo-2,5-dimethoxyamphetamine) .
- 841 | x. DOM (4-Methyl-2,5-dimethoxyamphetamine) .
- 842 | y. PMA (4-Methoxyamphetamine) .
- 843 | z. N-Ethylamphetamine .
- 844 | aa. 3,4-Methylenedioxy-N-hydroxyamphetamine .
- 845 | bb. 5-Methoxy-3,4-methylenedioxyamphetamine .
- 846 | cc. PMMA (4-Methoxymethamphetamine) .
- 847 | dd. N,N-Dimethylamphetamine .
- 848 | ee. 3,4,5-Trimethoxyamphetamine .
- 849 | ff. 4-APB (4-(2-Aminopropyl)benzofuran) .
- 850 | gg. 5-APB (5-(2-Aminopropyl)benzofuran) .

- 851 hh. 6-APB (6-(2-Aminopropyl)benzofuran).
- 852 ii. 7-APB (7-(2-Aminopropyl)benzofuran).
- 853 jj. 4-APDB (4-(2-Aminopropyl)-2,3-dihydrobenzofuran).
- 854 kk. 5-APDB (5-(2-Aminopropyl)-2,3-dihydrobenzofuran).
- 855 ll. 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran).
- 856 mm. 7-APDB (7-(2-Aminopropyl)-2,3-dihydrobenzofuran).
- 857 nn. 4-MAPB (4-(2-Methylaminopropyl)benzofuran).
- 858 oo. 5-MAPB (5-(2-Methylaminopropyl)benzofuran).
- 859 pp. 6-MAPB (6-(2-Methylaminopropyl)benzofuran).
- 860 qq. 7-MAPB (7-(2-Methylaminopropyl)benzofuran).
- 861 rr. 5-EAPB (5-(2-Ethylaminopropyl)benzofuran).
- 862 ss. 5-MAPDB (5-(2-Methylaminopropyl)-2,3-
- 863 dihydrobenzofuran),

864
 865 which does not include phenethylamine, mescaline as described in
 866 subparagraph 20., substituted cathinones as described in
 867 subparagraph 191., N-Benzyl phenethylamine compounds as
 868 described in subparagraph 193., or methamphetamine as described
 869 in subparagraph (2)(c)4.

870 193. N-Benzyl Phenethylamine Compounds.—Unless
 871 specifically excepted or unless listed in another schedule, or
 872 contained within a pharmaceutical product approved by the United
 873 States Food and Drug Administration, any material, compound,
 874 mixture, or preparation, including its salts, isomers, esters,
 875 or ethers, and salts of isomers, esters, or ethers, whenever the

876 | existence of such salts is possible within any of the following
877 | specific chemical designations, any compound containing a
878 | phenethylamine structure without a beta-keto group, with
879 | substitution on the nitrogen atom of the amino group with a
880 | benzyl substituent, with or without substitution on the phenyl
881 | or benzyl ring to any extent with alkyl, alkoxy, thio,
882 | alkylthio, halide, fused alkylenedioxy, fused furan, fused
883 | benzofuran, or fused tetrahydropyran substituents, whether or
884 | not further substituted on a ring to any extent, with or without
885 | substitution at the alpha position by any alkyl substituent,
886 | including, but not limited to:

887 | a. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2-
888 | methoxybenzyl)]phenethylamine).

889 | b. 25B-NBOH (4-Bromo-2,5-dimethoxy-[N-(2-
890 | hydroxybenzyl)]phenethylamine).

891 | c. 25B-NBF (4-Bromo-2,5-dimethoxy-[N-(2-
892 | fluorobenzyl)]phenethylamine).

893 | d. 25B-NBMD (4-Bromo-2,5-dimethoxy-[N-(2,3-
894 | methylenedioxybenzyl)]phenethylamine).

895 | e. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2-
896 | methoxybenzyl)]phenethylamine).

897 | f. 25I-NBOH (4-Iodo-2,5-dimethoxy-[N-(2-
898 | hydroxybenzyl)]phenethylamine).

899 | g. 25I-NBF (4-Iodo-2,5-dimethoxy-[N-(2-
900 | fluorobenzyl)]phenethylamine).

- 901 h. 25I-NBMD (4-Iodo-2,5-dimethoxy-[N-(2,3-
- 902 methylenedioxybenzyl)]phenethylamine).
- 903 i. 25T2-NBOMe (4-Methylthio-2,5-dimethoxy-[N-(2-
- 904 methoxybenzyl)]phenethylamine).
- 905 j. 25T4-NBOMe (4-Isopropylthio-2,5-dimethoxy-[N-(2-
- 906 methoxybenzyl)]phenethylamine).
- 907 k. 25T7-NBOMe (4-(n)-Propylthio-2,5-dimethoxy-[N-(2-
- 908 methoxybenzyl)]phenethylamine).
- 909 l. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2-
- 910 methoxybenzyl)]phenethylamine).
- 911 m. 25C-NBOH (4-Chloro-2,5-dimethoxy-[N-(2-
- 912 hydroxybenzyl)]phenethylamine).
- 913 n. 25C-NBF (4-Chloro-2,5-dimethoxy-[N-(2-
- 914 fluorobenzyl)]phenethylamine).
- 915 o. 25C-NBMD (4-Chloro-2,5-dimethoxy-[N-(2,3-
- 916 methylenedioxybenzyl)]phenethylamine).
- 917 p. 25H-NBOMe (2,5-Dimethoxy-[N-(2-
- 918 methoxybenzyl)]phenethylamine).
- 919 q. 25H-NBOH (2,5-Dimethoxy-[N-(2-
- 920 hydroxybenzyl)]phenethylamine).
- 921 r. 25H-NBF (2,5-Dimethoxy-[N-(2-
- 922 fluorobenzyl)]phenethylamine).
- 923 s. 25D-NBOMe (4-Methyl-2,5-dimethoxy-[N-(2-
- 924 methoxybenzyl)]phenethylamine),
- 925

926 | which does not include substituted cathinones as described in
927 | subparagraph 191.

928 | 194. Substituted Tryptamines.—Unless specifically excepted
929 | or unless listed in another schedule, or contained within a
930 | pharmaceutical product approved by the United States Food and
931 | Drug Administration, any material, compound, mixture, or
932 | preparation containing a 2-(1H-indol-3-yl)ethanamine, for
933 | example tryptamine, structure with or without mono- or di-
934 | substitution of the amine nitrogen with alkyl or alkenyl groups,
935 | or by inclusion of the amino nitrogen atom in a cyclic
936 | structure, whether or not substituted at the alpha position with
937 | an alkyl group, whether or not substituted on the indole ring to
938 | any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy
939 | groups, including, but not limited to:

- 940 | a. Alpha-Ethyltryptamine.
941 | b. Bufotenine.
942 | c. DET (Diethyltryptamine).
943 | d. DMT (Dimethyltryptamine).
944 | e. MET (N-Methyl-N-ethyltryptamine).
945 | f. DALT (N,N-Diallyltryptamine).
946 | g. EiPT (N-Ethyl-N-isopropyltryptamine).
947 | h. MiPT (N-Methyl-N-isopropyltryptamine).
948 | i. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
949 | j. 5-Hydroxy-N-methyltryptamine.
950 | k. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).

- 951 l. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
- 952 m. Methyltryptamine.
- 953 n. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
- 954 o. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
- 955 p. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
- 956 q. DiPT (N,N-Diisopropyltryptamine).
- 957 r. DPT (N,N-Dipropyltryptamine).
- 958 s. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
- 959 t. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
- 960 u. 4-AcO-DMT (4-Acetoxy-N,N-dimethyltryptamine).
- 961 v. 4-AcO-DiPT (4-Acetoxy-N,N-diisopropyltryptamine).
- 962 w. 4-Hydroxy-DET (4-Hydroxy-N,N-diethyltryptamine).
- 963 x. 4-Hydroxy-MET (4-Hydroxy-N-methyl-N-ethyltryptamine).
- 964 y. 4-Hydroxy-MiPT (4-Hydroxy-N-methyl-N-
- 965 isopropyltryptamine).
- 966 z. Methyl-alpha-ethyltryptamine.
- 967 aa. Bromo-DALT (Bromo-N,N-diallyltryptamine),

968
 969 which does not include tryptamine, psilocyn as described in
 970 subparagraph 34., or psilocybin as described in subparagraph 33.

971 195. Substituted Phenylcyclohexylamines.—Unless
 972 specifically excepted or unless listed in another schedule, or
 973 contained within a pharmaceutical product approved by the United
 974 States Food and Drug Administration, any material, compound,
 975 mixture, or preparation containing a phenylcyclohexylamine

976 structure, with or without any substitution on the phenyl ring,
977 any substitution on the cyclohexyl ring, any replacement of the
978 phenyl ring with a thiophenyl or benzothiophenyl ring, with or
979 without substitution on the amine with alkyl, dialkyl, or alkoxy
980 substituents, inclusion of the nitrogen in a cyclic structure,
981 or any combination of the above, including, but not limited to:

- 982 a. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
983 (Benocyclidine).
- 984 b. PCE (N-Ethyl-1-phenylcyclohexylamine) (Ethylamine analog
985 of phencyclidine).
- 986 c. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine
987 analog of phencyclidine).
- 988 d. PCPr (Phenylcyclohexylpropylamine).
- 989 e. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine) (Thiophene
990 analog of phencyclidine).
- 991 f. PCEEA (Phenylcyclohexyl(ethoxyethylamine)).
- 992 g. PCMPA (Phenylcyclohexyl(methoxypropylamine)).
- 993 h. Methoxetamine.
- 994 i. 3-Methoxy-PCE ((3-Methoxyphenyl)cyclohexylethylamine).
- 995 j. Bromo-PCP ((Bromophenyl)cyclohexylpiperidine).
- 996 k. Chloro-PCP ((Chlorophenyl)cyclohexylpiperidine).
- 997 l. Fluoro-PCP ((Fluorophenyl)cyclohexylpiperidine).
- 998 m. Hydroxy-PCP ((Hydroxyphenyl)cyclohexylpiperidine).
- 999 n. Methoxy-PCP ((Methoxyphenyl)cyclohexylpiperidine).
- 1000 o. Methyl-PCP ((Methylphenyl)cyclohexylpiperidine).

- 1001 p. Nitro-PCP ((Nitrophenyl)cyclohexylpiperidine).
- 1002 q. Oxo-PCP ((Oxophenyl)cyclohexylpiperidine).
- 1003 r. Amino-PCP ((Aminophenyl)cyclohexylpiperidine).
- 1004 196. Mitragynine or 7-Hydroxymitragynine, except for any
- 1005 drug product approved by the United States Food and Drug
- 1006 Administration which contains Mitragynine or 7-
- 1007 Hydroxymitragynine, including any of their isomers, esters,
- 1008 ethers, salts, and salts of isomers, esters, and ethers, if the
- 1009 existence of such isomers, esters, ethers, and salts is possible
- 1010 within the specific chemical designation.

1011 Section 2. Subsection (11) is added to section 893.13,
 1012 Florida Statutes, to read:

1013 893.13 Prohibited acts; penalties.—

1014 (11) Any prohibited act related to the controlled
 1015 substance described in s. 893.03(1)(c)196., shall be exclusively
 1016 governed by this subsection. A person who sells, delivers,
 1017 manufactures, or brings into this state, or possesses with
 1018 intent to sell, deliver, manufacture, or bring into this state,
 1019 the controlled substance described in s. 893.03(1)(c)196.,
 1020 commits a misdemeanor of the first degree, punishable as
 1021 provided in s. 775.082 or s. 775.083.

1022 Section 3. For the purpose of incorporating the amendment
 1023 made by this act to section 893.03, Florida Statutes, in a
 1024 reference thereto, paragraphs (a) and (g) of subsection (30) of
 1025 section 39.01, Florida Statutes, are reenacted to read:

1026 39.01 Definitions.—When used in this chapter, unless the
 1027 context otherwise requires:

1028 (30) "Harm" to a child's health or welfare can occur when
 1029 any person:

1030 (a) Inflicts or allows to be inflicted upon the child
 1031 physical, mental, or emotional injury. In determining whether
 1032 harm has occurred, the following factors must be considered in
 1033 evaluating any physical, mental, or emotional injury to a child:
 1034 the age of the child; any prior history of injuries to the
 1035 child; the location of the injury on the body of the child; the
 1036 multiplicity of the injury; and the type of trauma inflicted.
 1037 Such injury includes, but is not limited to:

- 1038 1. Willful acts that produce the following specific
 1039 injuries:
- 1040 a. Sprains, dislocations, or cartilage damage.
 - 1041 b. Bone or skull fractures.
 - 1042 c. Brain or spinal cord damage.
 - 1043 d. Intracranial hemorrhage or injury to other internal
 1044 organs.
 - 1045 e. Asphyxiation, suffocation, or drowning.
 - 1046 f. Injury resulting from the use of a deadly weapon.
 - 1047 g. Burns or scalding.
 - 1048 h. Cuts, lacerations, punctures, or bites.
 - 1049 i. Permanent or temporary disfigurement.
 - 1050 j. Permanent or temporary loss or impairment of a body

1051 part or function.

1052

1053 As used in this subparagraph, the term "willful" refers to the
1054 intent to perform an action, not to the intent to achieve a
1055 result or to cause an injury.

1056 2. Purposely giving a child poison, alcohol, drugs, or
1057 other substances that substantially affect the child's behavior,
1058 motor coordination, or judgment or that result in sickness or
1059 internal injury. For the purposes of this subparagraph, the term
1060 "drugs" means prescription drugs not prescribed for the child or
1061 not administered as prescribed, and controlled substances as
1062 outlined in Schedule I or Schedule II of s. 893.03.

1063 3. Leaving a child without adult supervision or
1064 arrangement appropriate for the child's age or mental or
1065 physical condition, so that the child is unable to care for the
1066 child's own needs or another's basic needs or is unable to
1067 exercise good judgment in responding to any kind of physical or
1068 emotional crisis.

1069 4. Inappropriate or excessively harsh disciplinary action
1070 that is likely to result in physical injury, mental injury as
1071 defined in this section, or emotional injury. The significance
1072 of any injury must be evaluated in light of the following
1073 factors: the age of the child; any prior history of injuries to
1074 the child; the location of the injury on the body of the child;
1075 the multiplicity of the injury; and the type of trauma

1076 | inflicted. Corporal discipline may be considered excessive or
 1077 | abusive when it results in any of the following or other similar
 1078 | injuries:

- 1079 | a. Sprains, dislocations, or cartilage damage.
- 1080 | b. Bone or skull fractures.
- 1081 | c. Brain or spinal cord damage.
- 1082 | d. Intracranial hemorrhage or injury to other internal
 1083 | organs.
- 1084 | e. Asphyxiation, suffocation, or drowning.
- 1085 | f. Injury resulting from the use of a deadly weapon.
- 1086 | g. Burns or scalding.
- 1087 | h. Cuts, lacerations, punctures, or bites.
- 1088 | i. Permanent or temporary disfigurement.
- 1089 | j. Permanent or temporary loss or impairment of a body
 1090 | part or function.
- 1091 | k. Significant bruises or welts.

1092 | (g) Exposes a child to a controlled substance or alcohol.
 1093 | Exposure to a controlled substance or alcohol is established by:

- 1094 | 1. A test, administered at birth, which indicated that the
 1095 | child's blood, urine, or meconium contained any amount of
 1096 | alcohol or a controlled substance or metabolites of such
 1097 | substances, the presence of which was not the result of medical
 1098 | treatment administered to the mother or the newborn infant; or
- 1099 | 2. Evidence of extensive, abusive, and chronic use of a
 1100 | controlled substance or alcohol by a parent when the child is

1101 demonstrably adversely affected by such usage.

1102

1103 As used in this paragraph, the term "controlled substance" means
1104 prescription drugs not prescribed for the parent or not
1105 administered as prescribed and controlled substances as outlined
1106 in Schedule I or Schedule II of s. 893.03.

1107 Section 4. For the purpose of incorporating the amendment
1108 made by this act to section 893.03, Florida Statutes, in a
1109 reference thereto, subsection (5) of section 316.193, Florida
1110 Statutes, is reenacted to read:

1111 316.193 Driving under the influence; penalties.—

1112 (5) The court shall place all offenders convicted of
1113 violating this section on monthly reporting probation and shall
1114 require completion of a substance abuse course conducted by a
1115 DUI program licensed by the department under s. 322.292, which
1116 must include a psychosocial evaluation of the offender. If the
1117 DUI program refers the offender to an authorized substance abuse
1118 treatment provider for substance abuse treatment, in addition to
1119 any sentence or fine imposed under this section, completion of
1120 all such education, evaluation, and treatment is a condition of
1121 reporting probation. The offender shall assume reasonable costs
1122 for such education, evaluation, and treatment. The referral to
1123 treatment resulting from a psychosocial evaluation shall not be
1124 waived without a supporting independent psychosocial evaluation
1125 conducted by an authorized substance abuse treatment provider

1126 appointed by the court, which shall have access to the DUI
1127 program's psychosocial evaluation before the independent
1128 psychosocial evaluation is conducted. The court shall review the
1129 results and recommendations of both evaluations before
1130 determining the request for waiver. The offender shall bear the
1131 full cost of this procedure. The term "substance abuse" means
1132 the abuse of alcohol or any substance named or described in
1133 Schedules I through V of s. 893.03. If an offender referred to
1134 treatment under this subsection fails to report for or complete
1135 such treatment or fails to complete the DUI program substance
1136 abuse education course and evaluation, the DUI program shall
1137 notify the court and the department of the failure. Upon receipt
1138 of the notice, the department shall cancel the offender's
1139 driving privilege, notwithstanding the terms of the court order
1140 or any suspension or revocation of the driving privilege. The
1141 department may temporarily reinstate the driving privilege on a
1142 restricted basis upon verification from the DUI program that the
1143 offender is currently participating in treatment and the DUI
1144 education course and evaluation requirement has been completed.
1145 If the DUI program notifies the department of the second failure
1146 to complete treatment, the department shall reinstate the
1147 driving privilege only after notice of completion of treatment
1148 from the DUI program. The organization that conducts the
1149 substance abuse education and evaluation may not provide
1150 required substance abuse treatment unless a waiver has been

1151 granted to that organization by the department. A waiver may be
1152 granted only if the department determines, in accordance with
1153 its rules, that the service provider that conducts the substance
1154 abuse education and evaluation is the most appropriate service
1155 provider and is licensed under chapter 397 or is exempt from
1156 such licensure. A statistical referral report shall be submitted
1157 quarterly to the department by each organization authorized to
1158 provide services under this section.

1159 Section 5. For the purpose of incorporating the amendment
1160 made by this act to section 893.03, Florida Statutes, in a
1161 reference thereto, paragraph (c) of subsection (2) of section
1162 322.2616, Florida Statutes, is reenacted to read:

1163 322.2616 Suspension of license; persons under 21 years of
1164 age; right to review.—

1165 (2)

1166 (c) When a driver subject to this section has a blood-
1167 alcohol or breath-alcohol level of 0.05 or higher, the
1168 suspension shall remain in effect until such time as the driver
1169 has completed a substance abuse course offered by a DUI program
1170 licensed by the department. The driver shall assume the
1171 reasonable costs for the substance abuse course. As part of the
1172 substance abuse course, the program shall conduct a substance
1173 abuse evaluation of the driver, and notify the parents or legal
1174 guardians of drivers under the age of 19 years of the results of
1175 the evaluation. The term "substance abuse" means the abuse of

1176 alcohol or any substance named or described in Schedules I
 1177 through V of s. 893.03. If a driver fails to complete the
 1178 substance abuse education course and evaluation, the driver
 1179 license shall not be reinstated by the department.

1180 Section 6. For the purpose of incorporating the amendment
 1181 made by this act to section 893.03, Florida Statutes, in a
 1182 reference thereto, subsection (5) of section 327.35, Florida
 1183 Statutes, is reenacted to read:

1184 327.35 Boating under the influence; penalties; "designated
 1185 drivers."—

1186 (5) In addition to any sentence or fine, the court shall
 1187 place any offender convicted of violating this section on
 1188 monthly reporting probation and shall require attendance at a
 1189 substance abuse course specified by the court; and the agency
 1190 conducting the course may refer the offender to an authorized
 1191 service provider for substance abuse evaluation and treatment,
 1192 in addition to any sentence or fine imposed under this section.
 1193 The offender shall assume reasonable costs for such education,
 1194 evaluation, and treatment, with completion of all such
 1195 education, evaluation, and treatment being a condition of
 1196 reporting probation. Treatment resulting from a psychosocial
 1197 evaluation may not be waived without a supporting psychosocial
 1198 evaluation conducted by an agency appointed by the court and
 1199 with access to the original evaluation. The offender shall bear
 1200 the cost of this procedure. The term "substance abuse" means the

1201 abuse of alcohol or any substance named or described in
 1202 Schedules I-V of s. 893.03.

1203 Section 7. For the purpose of incorporating the amendment
 1204 made by this act to section 893.03, Florida Statutes, in a
 1205 reference thereto, paragraph (b) of subsection (11) of section
 1206 440.102, Florida Statutes, is reenacted to read:

1207 440.102 Drug-free workplace program requirements.—The
 1208 following provisions apply to a drug-free workplace program
 1209 implemented pursuant to law or to rules adopted by the Agency
 1210 for Health Care Administration:

1211 (11) PUBLIC EMPLOYEES IN MANDATORY-TESTING OR SPECIAL-RISK
 1212 POSITIONS.—

1213 (b) An employee who is employed by a public employer in a
 1214 special-risk position may be discharged or disciplined by a
 1215 public employer for the first positive confirmed test result if
 1216 the drug confirmed is an illicit drug under s. 893.03. A
 1217 special-risk employee who is participating in an employee
 1218 assistance program or drug rehabilitation program may not be
 1219 allowed to continue to work in any special-risk or mandatory-
 1220 testing position of the public employer, but may be assigned to
 1221 a position other than a mandatory-testing position or placed on
 1222 leave while the employee is participating in the program.

1223 However, the employee shall be permitted to use any accumulated
 1224 annual leave credits before leave may be ordered without pay.

1225 Section 8. For the purpose of incorporating the amendment

1226 | made by this act to section 893.03, Florida Statutes, in a
 1227 | reference thereto, paragraph (e) of subsection (1) of section
 1228 | 458.3265, Florida Statutes, is reenacted to read:
 1229 | 458.3265 Pain-management clinics.—
 1230 | (1) REGISTRATION.—
 1231 | (e) The department shall deny registration to any pain-
 1232 | management clinic owned by or with any contractual or employment
 1233 | relationship with a physician:
 1234 | 1. Whose Drug Enforcement Administration number has ever
 1235 | been revoked.
 1236 | 2. Whose application for a license to prescribe, dispense,
 1237 | or administer a controlled substance has been denied by any
 1238 | jurisdiction.
 1239 | 3. Who has been convicted of or pleaded guilty or nolo
 1240 | contendere to, regardless of adjudication, an offense that
 1241 | constitutes a felony for receipt of illicit and diverted drugs,
 1242 | including a controlled substance listed in Schedule I, Schedule
 1243 | II, Schedule III, Schedule IV, or Schedule V of s. 893.03, in
 1244 | this state, any other state, or the United States.
 1245 | Section 9. For the purpose of incorporating the amendment
 1246 | made by this act to section 893.03, Florida Statutes, in a
 1247 | reference thereto, paragraph (e) of subsection (1) of section
 1248 | 459.0137, Florida Statutes, is reenacted to read:
 1249 | 459.0137 Pain-management clinics.—
 1250 | (1) REGISTRATION.—

1251 (e) The department shall deny registration to any pain-
 1252 management clinic owned by or with any contractual or employment
 1253 relationship with a physician:

1254 1. Whose Drug Enforcement Administration number has ever
 1255 been revoked.

1256 2. Whose application for a license to prescribe, dispense,
 1257 or administer a controlled substance has been denied by any
 1258 jurisdiction.

1259 3. Who has been convicted of or pleaded guilty or nolo
 1260 contendere to, regardless of adjudication, an offense that
 1261 constitutes a felony for receipt of illicit and diverted drugs,
 1262 including a controlled substance listed in Schedule I, Schedule
 1263 II, Schedule III, Schedule IV, or Schedule V of s. 893.03, in
 1264 this state, any other state, or the United States.

1265 Section 10. For the purpose of incorporating the amendment
 1266 made by this act to section 893.03, Florida Statutes, in
 1267 references thereto, paragraph (a) of subsection (1) and
 1268 subsection (4) of section 782.04, Florida Statutes, are
 1269 reenacted to read:

1270 782.04 Murder.—

1271 (1) (a) The unlawful killing of a human being:

1272 1. When perpetrated from a premeditated design to effect
 1273 the death of the person killed or any human being;

1274 2. When committed by a person engaged in the perpetration
 1275 of, or in the attempt to perpetrate, any:

- 1276 a. Trafficking offense prohibited by s. 893.135(1),
- 1277 b. Arson,
- 1278 c. Sexual battery,
- 1279 d. Robbery,
- 1280 e. Burglary,
- 1281 f. Kidnapping,
- 1282 g. Escape,
- 1283 h. Aggravated child abuse,
- 1284 i. Aggravated abuse of an elderly person or disabled
- 1285 adult,
- 1286 j. Aircraft piracy,
- 1287 k. Unlawful throwing, placing, or discharging of a
- 1288 destructive device or bomb,
- 1289 l. Carjacking,
- 1290 m. Home-invasion robbery,
- 1291 n. Aggravated stalking,
- 1292 o. Murder of another human being,
- 1293 p. Resisting an officer with violence to his or her
- 1294 person,
- 1295 q. Aggravated fleeing or eluding with serious bodily
- 1296 injury or death,
- 1297 r. Felony that is an act of terrorism or is in furtherance
- 1298 of an act of terrorism,
- 1299 s. Human trafficking; or
- 1300 3. Which resulted from the unlawful distribution of any

1301 substance controlled under s. 893.03(1), cocaine as described in
 1302 s. 893.03(2)(a)4., opium or any synthetic or natural salt,
 1303 compound, derivative, or preparation of opium, or methadone by a
 1304 person 18 years of age or older, when such drug is proven to be
 1305 the proximate cause of the death of the user,

1306
 1307 is murder in the first degree and constitutes a capital felony,
 1308 punishable as provided in s. 775.082.

1309 (4) The unlawful killing of a human being, when
 1310 perpetrated without any design to effect death, by a person
 1311 engaged in the perpetration of, or in the attempt to perpetrate,
 1312 any felony other than any:

- 1313 (a) Trafficking offense prohibited by s. 893.135(1),
- 1314 (b) Arson,
- 1315 (c) Sexual battery,
- 1316 (d) Robbery,
- 1317 (e) Burglary,
- 1318 (f) Kidnapping,
- 1319 (g) Escape,
- 1320 (h) Aggravated child abuse,
- 1321 (i) Aggravated abuse of an elderly person or disabled
 1322 adult,
- 1323 (j) Aircraft piracy,
- 1324 (k) Unlawful throwing, placing, or discharging of a
 1325 destructive device or bomb,

1326 (l) Unlawful distribution of any substance controlled
 1327 under s. 893.03(1), cocaine as described in s. 893.03(2)(a)4.,
 1328 or opium or any synthetic or natural salt, compound, derivative,
 1329 or preparation of opium by a person 18 years of age or older,
 1330 when such drug is proven to be the proximate cause of the death
 1331 of the user,

1332 (m) Carjacking,

1333 (n) Home-invasion robbery,

1334 (o) Aggravated stalking,

1335 (p) Murder of another human being,

1336 (q) Aggravated fleeing or eluding with serious bodily
 1337 injury or death,

1338 (r) Resisting an officer with violence to his or her
 1339 person, or

1340 (s) Felony that is an act of terrorism or is in
 1341 furtherance of an act of terrorism,

1342

1343 is murder in the third degree and constitutes a felony of the
 1344 second degree, punishable as provided in s. 775.082, s. 775.083,
 1345 or s. 775.084.

1346 Section 11. For the purpose of incorporating the amendment
 1347 made by this act to section 893.03, Florida Statutes, in a
 1348 reference thereto, paragraph (a) of subsection (2) of section
 1349 787.06, Florida Statutes, is reenacted to read:

1350 787.06 Human trafficking.—

- 1351 (2) As used in this section, the term:
- 1352 (a) "Coercion" means:
- 1353 1. Using or threatening to use physical force against any
- 1354 person;
- 1355 2. Restraining, isolating, or confining or threatening to
- 1356 restrain, isolate, or confine any person without lawful
- 1357 authority and against her or his will;
- 1358 3. Using lending or other credit methods to establish a
- 1359 debt by any person when labor or services are pledged as a
- 1360 security for the debt, if the value of the labor or services as
- 1361 reasonably assessed is not applied toward the liquidation of the
- 1362 debt, the length and nature of the labor or services are not
- 1363 respectively limited and defined;
- 1364 4. Destroying, concealing, removing, confiscating,
- 1365 withholding, or possessing any actual or purported passport,
- 1366 visa, or other immigration document, or any other actual or
- 1367 purported government identification document, of any person;
- 1368 5. Causing or threatening to cause financial harm to any
- 1369 person;
- 1370 6. Enticing or luring any person by fraud or deceit; or
- 1371 7. Providing a controlled substance as outlined in
- 1372 Schedule I or Schedule II of s. 893.03 to any person for the
- 1373 purpose of exploitation of that person.

1374 Section 12. For the purpose of incorporating the amendment

1375 made by this act to section 893.03, Florida Statutes, in

1376 references thereto, Section 817.563, Florida Statutes, is
 1377 reenacted to read:

1378 817.563 Controlled substance named or described in s.
 1379 893.03; sale of substance in lieu thereof.—It is unlawful for
 1380 any person to agree, consent, or in any manner offer to
 1381 unlawfully sell to any person a controlled substance named or
 1382 described in s. 893.03 and then sell to such person any other
 1383 substance in lieu of such controlled substance. Any person who
 1384 violates this section with respect to:

1385 (1) A controlled substance named or described in s.
 1386 893.03(1), (2), (3), or (4) is guilty of a felony of the third
 1387 degree, punishable as provided in s. 775.082, s. 775.083, or s.
 1388 775.084.

1389 (2) A controlled substance named or described in s.
 1390 893.03(5) is guilty of a misdemeanor of the second degree,
 1391 punishable as provided in s. 775.082 or s. 775.083.

1392 Section 13. For the purpose of incorporating the amendment
 1393 made by this act to section 893.03, Florida Statutes, in
 1394 references thereto, paragraph (a) of subsection (1) and
 1395 subsection (2) of section 831.31, Florida Statutes, are
 1396 reenacted to read:

1397 831.31 Counterfeit controlled substance; sale,
 1398 manufacture, delivery, or possession with intent to sell,
 1399 manufacture, or deliver.—

1400 (1) It is unlawful for any person to sell, manufacture, or

1401 deliver, or to possess with intent to sell, manufacture, or
 1402 deliver, a counterfeit controlled substance. Any person who
 1403 violates this subsection with respect to:

1404 (a) A controlled substance named or described in s.
 1405 893.03(1), (2), (3), or (4) is guilty of a felony of the third
 1406 degree, punishable as provided in s. 775.082, s. 775.083, or s.
 1407 775.084.

1408 (2) For purposes of this section, "counterfeit controlled
 1409 substance" means:

1410 (a) A controlled substance named or described in s. 893.03
 1411 which, or the container or labeling of which, without
 1412 authorization bears the trademark, trade name, or other
 1413 identifying mark, imprint, or number, or any likeness thereof,
 1414 of a manufacturer other than the person who in fact manufactured
 1415 the controlled substance; or

1416 (b) Any substance which is falsely identified as a
 1417 controlled substance named or described in s. 893.03.

1418 Section 14. For the purpose of incorporating the amendment
 1419 made by this act to section 893.03, Florida Statutes, in a
 1420 reference thereto, paragraph (c) of subsection (1) of section
 1421 856.015, Florida Statutes, is reenacted to read:

1422 856.015 Open house parties.—

1423 (1) Definitions.—As used in this section:

1424 (c) "Drug" means a controlled substance, as that term is
 1425 defined in ss. 893.02(4) and 893.03.

1426 Section 15. For the purpose of incorporating the amendment
 1427 made by this act to section 893.03, Florida Statutes, in a
 1428 reference thereto, subsection (4) of section 893.02, Florida
 1429 Statutes, is reenacted to read:

1430 893.02 Definitions.—The following words and phrases as
 1431 used in this chapter shall have the following meanings, unless
 1432 the context otherwise requires:

1433 (4) "Controlled substance" means any substance named or
 1434 described in Schedules I-V of s. 893.03. Laws controlling the
 1435 manufacture, distribution, preparation, dispensing, or
 1436 administration of such substances are drug abuse laws.

1437 Section 16. For the purpose of incorporating the amendment
 1438 made by this act to section 893.03, Florida Statutes, in
 1439 references thereto, subsection (2), paragraph (a) of subsection
 1440 (7), and paragraph (a) of subsection (8) of section 893.035,
 1441 Florida Statutes, are reenacted to read:

1442 893.035 Control of new substances; findings of fact;
 1443 delegation of authority to Attorney General to control
 1444 substances by rule.—

1445 (2) The Attorney General shall apply the provisions of
 1446 this section to any substance not currently controlled under the
 1447 provisions of s. 893.03. The Attorney General may by rule:

1448 (a) Add a substance to a schedule established by s.
 1449 893.03, or transfer a substance between schedules, if he or she
 1450 finds that it has a potential for abuse and he or she makes with

1451 respect to it the other findings appropriate for classification
 1452 in the particular schedule under s. 893.03 in which it is to be
 1453 placed.

1454 (b) Remove a substance previously added to a schedule if
 1455 he or she finds the substance does not meet the requirements for
 1456 inclusion in that schedule.

1457
 1458 Rules adopted under this section shall be made pursuant to the
 1459 rulemaking procedures prescribed by chapter 120.

1460 (7) (a) If the Attorney General finds that the scheduling
 1461 of a substance in Schedule I of s. 893.03 on a temporary basis
 1462 is necessary to avoid an imminent hazard to the public safety,
 1463 he or she may by rule and without regard to the requirements of
 1464 subsection (5) relating to the Department of Health and the
 1465 Department of Law Enforcement schedule such substance in
 1466 Schedule I if the substance is not listed in any other schedule
 1467 of s. 893.03. The Attorney General shall be required to
 1468 consider, with respect to his or her finding of imminent hazard
 1469 to the public safety, only those factors set forth in paragraphs
 1470 (3) (a) and (4) (d), (e), and (f), including actual abuse,
 1471 diversion from legitimate channels, and clandestine importation,
 1472 manufacture, or distribution.

1473 (8) (a) Upon the effective date of a rule adopted pursuant
 1474 to this section adding or transferring a substance to a schedule
 1475 under s. 893.03, such substance shall be deemed included in that

1476 | schedule, and all provisions of this chapter applicable to
1477 | substances in that schedule shall be deemed applicable to such
1478 | substance.

1479 | Section 17. For the purpose of incorporating the amendment
1480 | made by this act to section 893.03, Florida Statutes, in
1481 | references thereto, paragraph (a) of subsection (2) and
1482 | subsection (5) of section 893.0356, Florida Statutes, are
1483 | reenacted to read:

1484 | 893.0356 Control of new substances; findings of fact;
1485 | "controlled substance analog" defined.—

1486 | (2) (a) As used in this section, "controlled substance
1487 | analog" means a substance which, due to its chemical structure
1488 | and potential for abuse, meets the following criteria:

1489 | 1. Is substantially similar to that of a controlled
1490 | substance listed in Schedule I or Schedule II of s. 893.03; and

1491 | 2. Has a stimulant, depressant, or hallucinogenic effect
1492 | on the central nervous system or is represented or intended to
1493 | have a stimulant, depressant, or hallucinogenic effect on the
1494 | central nervous system substantially similar to or greater than
1495 | that of a controlled substance listed in Schedule I or Schedule
1496 | II of s. 893.03.

1497 | (5) A controlled substance analog shall, for purposes of
1498 | drug abuse prevention and control, be treated as the highest
1499 | scheduled controlled substance of which it is a controlled
1500 | substance analog in s. 893.03.

1501 Section 18. For the purpose of incorporating the amendment
 1502 made by this act to section 893.03, Florida Statutes, in a
 1503 reference thereto, paragraph (d) of subsection (1) of section
 1504 893.05, Florida Statutes, is reenacted to read:

1505 893.05 Practitioners and persons administering controlled
 1506 substances in their absence.—

1507 (1)

1508 (d) A certified optometrist licensed under chapter 463 may
 1509 not administer or prescribe a controlled substance listed in
 1510 Schedule I or Schedule II of s. 893.03.

1511 Section 19. For the purpose of incorporating the amendment
 1512 made by this act to section 893.03, Florida Statutes, in
 1513 references thereto, paragraphs (b), (c), and (d) of subsection
 1514 (2) of section 893.12, Florida Statutes, are reenacted to read:

1515 893.12 Contraband; seizure, forfeiture, sale.—

1516 (2)

1517 (b) All real property, including any right, title,
 1518 leasehold interest, and other interest in the whole of any lot
 1519 or tract of land and any appurtenances or improvements, which
 1520 real property is used, or intended to be used, in any manner or
 1521 part, to commit or to facilitate the commission of, or which
 1522 real property is acquired with proceeds obtained as a result of,
 1523 a violation of any provision of this chapter related to a
 1524 controlled substance described in s. 893.03(1) or (2) may be
 1525 seized and forfeited as provided by the Florida Contraband

1526 Forfeiture Act except that no property shall be forfeited under
1527 this paragraph to the extent of an interest of an owner or
1528 lienholder by reason of any act or omission established by that
1529 owner or lienholder to have been committed or omitted without
1530 the knowledge or consent of that owner or lienholder.

1531 (c) All moneys, negotiable instruments, securities, and
1532 other things of value furnished or intended to be furnished by
1533 any person in exchange for a controlled substance described in
1534 s. 893.03(1) or (2) or a listed chemical in violation of any
1535 provision of this chapter, all proceeds traceable to such an
1536 exchange, and all moneys, negotiable instruments, and securities
1537 used or intended to be used to facilitate any violation of any
1538 provision of this chapter or which are acquired with proceeds
1539 obtained in violation of any provision of this chapter may be
1540 seized and forfeited as provided by the Florida Contraband
1541 Forfeiture Act, except that no property shall be forfeited under
1542 this paragraph to the extent of an interest of an owner or
1543 lienholder by reason of any act or omission established by that
1544 owner or lienholder to have been committed or omitted without
1545 the knowledge or consent of that owner or lienholder.

1546 (d) All books, records, and research, including formulas,
1547 microfilm, tapes, and data which are used, or intended for use,
1548 or which are acquired with proceeds obtained, in violation of
1549 any provision of this chapter related to a controlled substance
1550 described in s. 893.03(1) or (2) or a listed chemical may be

1551 seized and forfeited as provided by the Florida Contraband
 1552 Forfeiture Act.

1553 Section 20. For the purpose of incorporating the amendment
 1554 made by this act to section 893.03, Florida Statutes, in
 1555 references thereto, paragraphs (a), (c), (d), (e), (f), and (h)
 1556 of subsection (1), paragraph (a) of subsection (2), paragraph
 1557 (b) of subsection (4), paragraph (b) of subsection (5), and
 1558 paragraph (a) of subsection (7) of section 893.13, Florida
 1559 Statutes, are reenacted to read:

1560 893.13 Prohibited acts; penalties.—

1561 (1) (a) Except as authorized by this chapter and chapter
 1562 499, a person may not sell, manufacture, or deliver, or possess
 1563 with intent to sell, manufacture, or deliver, a controlled
 1564 substance. A person who violates this provision with respect to:

1565 1. A controlled substance named or described in s.
 1566 893.03(1) (a), (1) (b), (1) (d), (2) (a), (2) (b), or (2) (c) 4.
 1567 commits a felony of the second degree, punishable as provided in
 1568 s. 775.082, s. 775.083, or s. 775.084.

1569 2. A controlled substance named or described in s.
 1570 893.03(1) (c), (2) (c) 1., (2) (c) 2., (2) (c) 3., (2) (c) 5., (2) (c) 6.,
 1571 (2) (c) 7., (2) (c) 8., (2) (c) 9., (3), or (4) commits a felony of
 1572 the third degree, punishable as provided in s. 775.082, s.
 1573 775.083, or s. 775.084.

1574 3. A controlled substance named or described in s.
 1575 893.03(5) commits a misdemeanor of the first degree, punishable

1576 as provided in s. 775.082 or s. 775.083.

1577 (c) Except as authorized by this chapter, a person may not
 1578 sell, manufacture, or deliver, or possess with intent to sell,
 1579 manufacture, or deliver, a controlled substance in, on, or
 1580 within 1,000 feet of the real property comprising a child care
 1581 facility as defined in s. 402.302 or a public or private
 1582 elementary, middle, or secondary school between the hours of 6
 1583 a.m. and 12 midnight, or at any time in, on, or within 1,000
 1584 feet of real property comprising a state, county, or municipal
 1585 park, a community center, or a publicly owned recreational
 1586 facility. As used in this paragraph, the term "community center"
 1587 means a facility operated by a nonprofit community-based
 1588 organization for the provision of recreational, social, or
 1589 educational services to the public. A person who violates this
 1590 paragraph with respect to:

1591 1. A controlled substance named or described in s.
 1592 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)4.
 1593 commits a felony of the first degree, punishable as provided in
 1594 s. 775.082, s. 775.083, or s. 775.084. The defendant must be
 1595 sentenced to a minimum term of imprisonment of 3 calendar years
 1596 unless the offense was committed within 1,000 feet of the real
 1597 property comprising a child care facility as defined in s.
 1598 402.302.

1599 2. A controlled substance named or described in s.
 1600 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6.,

1601 (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) commits a felony of
 1602 the second degree, punishable as provided in s. 775.082, s.
 1603 775.083, or s. 775.084.

1604 3. Any other controlled substance, except as lawfully
 1605 sold, manufactured, or delivered, must be sentenced to pay a
 1606 \$500 fine and to serve 100 hours of public service in addition
 1607 to any other penalty prescribed by law.

1608
 1609 This paragraph does not apply to a child care facility unless
 1610 the owner or operator of the facility posts a sign that is not
 1611 less than 2 square feet in size with a word legend identifying
 1612 the facility as a licensed child care facility and that is
 1613 posted on the property of the child care facility in a
 1614 conspicuous place where the sign is reasonably visible to the
 1615 public.

1616 (d) Except as authorized by this chapter, a person may not
 1617 sell, manufacture, or deliver, or possess with intent to sell,
 1618 manufacture, or deliver, a controlled substance in, on, or
 1619 within 1,000 feet of the real property comprising a public or
 1620 private college, university, or other postsecondary educational
 1621 institution. A person who violates this paragraph with respect
 1622 to:

1623 1. A controlled substance named or described in s.
 1624 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)4.
 1625 commits a felony of the first degree, punishable as provided in

1626 | s. 775.082, s. 775.083, or s. 775.084.

1627 | 2. A controlled substance named or described in s.
 1628 | 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6.,
 1629 | (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) commits a felony of
 1630 | the second degree, punishable as provided in s. 775.082, s.
 1631 | 775.083, or s. 775.084.

1632 | 3. Any other controlled substance, except as lawfully
 1633 | sold, manufactured, or delivered, must be sentenced to pay a
 1634 | \$500 fine and to serve 100 hours of public service in addition
 1635 | to any other penalty prescribed by law.

1636 | (e) Except as authorized by this chapter, a person may not
 1637 | sell, manufacture, or deliver, or possess with intent to sell,
 1638 | manufacture, or deliver, a controlled substance not authorized
 1639 | by law in, on, or within 1,000 feet of a physical place for
 1640 | worship at which a church or religious organization regularly
 1641 | conducts religious services or within 1,000 feet of a
 1642 | convenience business as defined in s. 812.171. A person who
 1643 | violates this paragraph with respect to:

1644 | 1. A controlled substance named or described in s.
 1645 | 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)4.
 1646 | commits a felony of the first degree, punishable as provided in
 1647 | s. 775.082, s. 775.083, or s. 775.084.

1648 | 2. A controlled substance named or described in s.
 1649 | 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6.,
 1650 | (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) commits a felony of

1651 the second degree, punishable as provided in s. 775.082, s.
 1652 775.083, or s. 775.084.

1653 3. Any other controlled substance, except as lawfully
 1654 sold, manufactured, or delivered, must be sentenced to pay a
 1655 \$500 fine and to serve 100 hours of public service in addition
 1656 to any other penalty prescribed by law.

1657 (f) Except as authorized by this chapter, a person may not
 1658 sell, manufacture, or deliver, or possess with intent to sell,
 1659 manufacture, or deliver, a controlled substance in, on, or
 1660 within 1,000 feet of the real property comprising a public
 1661 housing facility at any time. As used in this section, the term
 1662 "real property comprising a public housing facility" means real
 1663 property, as defined in s. 421.03(12), of a public corporation
 1664 created as a housing authority pursuant to part I of chapter
 1665 421. A person who violates this paragraph with respect to:

1666 1. A controlled substance named or described in s.
 1667 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)4.
 1668 commits a felony of the first degree, punishable as provided in
 1669 s. 775.082, s. 775.083, or s. 775.084.

1670 2. A controlled substance named or described in s.
 1671 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6.,
 1672 (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) commits a felony of
 1673 the second degree, punishable as provided in s. 775.082, s.
 1674 775.083, or s. 775.084.

1675 3. Any other controlled substance, except as lawfully

1676 sold, manufactured, or delivered, must be sentenced to pay a
 1677 \$500 fine and to serve 100 hours of public service in addition
 1678 to any other penalty prescribed by law.

1679 (h) Except as authorized by this chapter, a person may not
 1680 sell, manufacture, or deliver, or possess with intent to sell,
 1681 manufacture, or deliver, a controlled substance in, on, or
 1682 within 1,000 feet of the real property comprising an assisted
 1683 living facility, as that term is used in chapter 429. A person
 1684 who violates this paragraph with respect to:

1685 1. A controlled substance named or described in s.
 1686 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)4.
 1687 commits a felony of the first degree, punishable as provided in
 1688 s. 775.082, s. 775.083, or s. 775.084.

1689 2. A controlled substance named or described in s.
 1690 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6.,
 1691 (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) commits a felony of
 1692 the second degree, punishable as provided in s. 775.082, s.
 1693 775.083, or s. 775.084.

1694 3. Any other controlled substance, except as lawfully
 1695 sold, manufactured, or delivered, must be sentenced to pay a
 1696 \$500 fine and to serve 100 hours of public service in addition
 1697 to any other penalty prescribed by law.

1698 (2)(a) Except as authorized by this chapter and chapter
 1699 499, a person may not purchase, or possess with intent to
 1700 purchase, a controlled substance. A person who violates this

1701 provision with respect to:

1702 1. A controlled substance named or described in s.
1703 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)4.
1704 commits a felony of the second degree, punishable as provided in
1705 s. 775.082, s. 775.083, or s. 775.084.

1706 2. A controlled substance named or described in s.
1707 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6.,
1708 (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) commits a felony of
1709 the third degree, punishable as provided in s. 775.082, s.
1710 775.083, or s. 775.084.

1711 3. A controlled substance named or described in s.
1712 893.03(5) commits a misdemeanor of the first degree, punishable
1713 as provided in s. 775.082 or s. 775.083.

1714 (4) Except as authorized by this chapter, a person 18
1715 years of age or older may not deliver any controlled substance
1716 to a person younger than 18 years of age, use or hire a person
1717 younger than 18 years of age as an agent or employee in the sale
1718 or delivery of such a substance, or use such person to assist in
1719 avoiding detection or apprehension for a violation of this
1720 chapter. A person who violates this paragraph with respect to:

1721 (b) A controlled substance named or described in s.
1722 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6.,
1723 (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) commits a felony of
1724 the second degree, punishable as provided in s. 775.082, s.
1725 775.083, or s. 775.084.

1726
 1727 Imposition of sentence may not be suspended or deferred, and the
 1728 person so convicted may not be placed on probation.

1729 (5) A person may not bring into this state any controlled
 1730 substance unless the possession of such controlled substance is
 1731 authorized by this chapter or unless such person is licensed to
 1732 do so by the appropriate federal agency. A person who violates
 1733 this provision with respect to:

1734 (b) A controlled substance named or described in s.
 1735 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6.,
 1736 (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) commits a felony of
 1737 the third degree, punishable as provided in s. 775.082, s.
 1738 775.083, or s. 775.084.

1739 (7)(a) A person may not:

1740 1. Distribute or dispense a controlled substance in
 1741 violation of this chapter.

1742 2. Refuse or fail to make, keep, or furnish any record,
 1743 notification, order form, statement, invoice, or information
 1744 required under this chapter.

1745 3. Refuse entry into any premises for any inspection or
 1746 refuse to allow any inspection authorized by this chapter.

1747 4. Distribute a controlled substance named or described in
 1748 s. 893.03(1) or (2) except pursuant to an order form as required
 1749 by s. 893.06.

1750 5. Keep or maintain any store, shop, warehouse, dwelling,

1751 building, vehicle, boat, aircraft, or other structure or place
1752 which is resorted to by persons using controlled substances in
1753 violation of this chapter for the purpose of using these
1754 substances, or which is used for keeping or selling them in
1755 violation of this chapter.

1756 6. Use to his or her own personal advantage, or reveal,
1757 any information obtained in enforcement of this chapter except
1758 in a prosecution or administrative hearing for a violation of
1759 this chapter.

1760 7. Possess a prescription form unless it has been signed
1761 by the practitioner whose name appears printed thereon and
1762 completed. This subparagraph does not apply if the person in
1763 possession of the form is the practitioner whose name appears
1764 printed thereon, an agent or employee of that practitioner, a
1765 pharmacist, or a supplier of prescription forms who is
1766 authorized by that practitioner to possess those forms.

1767 8. Withhold information from a practitioner from whom the
1768 person seeks to obtain a controlled substance or a prescription
1769 for a controlled substance that the person making the request
1770 has received a controlled substance or a prescription for a
1771 controlled substance of like therapeutic use from another
1772 practitioner within the previous 30 days.

1773 9. Acquire or obtain, or attempt to acquire or obtain,
1774 possession of a controlled substance by misrepresentation,
1775 fraud, forgery, deception, or subterfuge.

1776 10. Affix any false or forged label to a package or
1777 receptacle containing a controlled substance.

1778 11. Furnish false or fraudulent material information in,
1779 or omit any material information from, any report or other
1780 document required to be kept or filed under this chapter or any
1781 record required to be kept by this chapter.

1782 12. Store anhydrous ammonia in a container that is not
1783 approved by the United States Department of Transportation to
1784 hold anhydrous ammonia or is not constructed in accordance with
1785 sound engineering, agricultural, or commercial practices.

1786 13. With the intent to obtain a controlled substance or
1787 combination of controlled substances that are not medically
1788 necessary for the person or an amount of a controlled substance
1789 or substances that is not medically necessary for the person,
1790 obtain or attempt to obtain from a practitioner a controlled
1791 substance or a prescription for a controlled substance by
1792 misrepresentation, fraud, forgery, deception, subterfuge, or
1793 concealment of a material fact. For purposes of this
1794 subparagraph, a material fact includes whether the person has an
1795 existing prescription for a controlled substance issued for the
1796 same period of time by another practitioner or as described in
1797 subparagraph 8.

1798 Section 21. For the purpose of incorporating the amendment
1799 made by this act to section 893.03, Florida Statutes, in
1800 references thereto, paragraphs (b), (c), and (e) of subsection

1801 (3) of section 921.0022, Florida Statutes, are reenacted to
 1802 read:

1803 921.0022 Criminal Punishment Code; offense severity
 1804 ranking chart.—

1805 (3) OFFENSE SEVERITY RANKING CHART

1806 (b) LEVEL 2

1807

Florida Statute	Felony Degree	Description
--------------------	------------------	-------------

1808

379.2431 (1) (e) 3.	3rd	Possession of 11 or fewer marine turtle eggs in violation of the Marine Turtle Protection Act.
------------------------	-----	---

1809

379.2431 (1) (e) 4.	3rd	Possession of more than 11 marine turtle eggs in violation of the Marine Turtle Protection Act.
------------------------	-----	--

1810

403.413 (6) (c)	3rd	Dumps waste litter exceeding 500 lbs. in weight or 100 cubic feet in volume or any quantity for commercial purposes, or hazardous waste.
-----------------	-----	--

HB 183

2017

1811	517.07 (2)	3rd	Failure to furnish a prospectus meeting requirements.
1812	590.28 (1)	3rd	Intentional burning of lands.
1813	784.05 (3)	3rd	Storing or leaving a loaded firearm within reach of minor who uses it to inflict injury or death.
1814	787.04 (1)	3rd	In violation of court order, take, entice, etc., minor beyond state limits.
1815	806.13 (1) (b) 3.	3rd	Criminal mischief; damage \$1,000 or more to public communication or any other public service.
1816	810.061 (2)	3rd	Impairing or impeding telephone or power to a dwelling; facilitating or furthering burglary.
1817			

1818	810.09 (2) (e)	3rd	Trespassing on posted commercial horticulture property.
1819	812.014 (2) (c) 1.	3rd	Grand theft, 3rd degree; \$300 or more but less than \$5,000.
1820	812.014 (2) (d)	3rd	Grand theft, 3rd degree; \$100 or more but less than \$300, taken from unenclosed curtilage of dwelling.
1821	812.015 (7)	3rd	Possession, use, or attempted use of an antishoplifting or inventory control device countermeasure.
1822	817.234 (1) (a) 2.	3rd	False statement in support of insurance claim.
1823	817.481 (3) (a)	3rd	Obtain credit or purchase with false, expired, counterfeit, etc., credit card, value over \$300.

HB 183

2017

1824	817.52 (3)	3rd	Failure to redeliver hired vehicle.
1825	817.54	3rd	With intent to defraud, obtain mortgage note, etc., by false representation.
1826	817.60 (5)	3rd	Dealing in credit cards of another.
1827	817.60 (6) (a)	3rd	Forgery; purchase goods, services with false card.
1828	817.61	3rd	Fraudulent use of credit cards over \$100 or more within 6 months.
1829	826.04	3rd	Knowingly marries or has sexual intercourse with person to whom related.
1830	831.01	3rd	Forgery.
	831.02	3rd	Uttering forged instrument; utters or publishes alteration

HB 183

2017

1831	831.07	3rd	with intent to defraud. Forging bank bills, checks, drafts, or promissory notes.
1832	831.08	3rd	Possessing 10 or more forged notes, bills, checks, or drafts.
1833	831.09	3rd	Uttering forged notes, bills, checks, drafts, or promissory notes.
1834	831.11	3rd	Bringing into the state forged bank bills, checks, drafts, or notes.
1835	832.05 (3) (a)	3rd	Cashing or depositing item with intent to defraud.
1836	843.08	3rd	False personation.
1837	893.13 (2) (a) 2.	3rd	Purchase of any s. 893.03 (1) (c), (2) (c) 1., (2) (c) 2., (2) (c) 3., (2) (c) 5.,

HB 183

2017

1838			(2) (c) 6., (2) (c) 7., (2) (c) 8., (2) (c) 9., (3), or (4) drugs other than cannabis.
	893.147(2)	3rd	Manufacture or delivery of drug paraphernalia.
1839			
1840	(c) LEVEL 3		
1841			
	Florida	Felony	
	Statute	Degree	Description
1842			
	119.10(2)(b)	3rd	Unlawful use of confidential information from police reports.
1843			
	316.066 (3)(b)-(d)	3rd	Unlawfully obtaining or using confidential crash reports.
1844			
	316.193(2)(b)	3rd	Felony DUI, 3rd conviction.
1845			
	316.1935(2)	3rd	Fleeing or attempting to elude law enforcement officer in patrol vehicle with siren and lights activated.

HB 183

2017

1846	319.30(4)	3rd	Possession by junkyard of motor vehicle with identification number plate removed.
1847	319.33(1)(a)	3rd	Alter or forge any certificate of title to a motor vehicle or mobile home.
1848	319.33(1)(c)	3rd	Procure or pass title on stolen vehicle.
1849	319.33(4)	3rd	With intent to defraud, possess, sell, etc., a blank, forged, or unlawfully obtained title or registration.
1850	327.35(2)(b)	3rd	Felony BUI.
1851	328.05(2)	3rd	Possess, sell, or counterfeit fictitious, stolen, or fraudulent titles or bills of sale of vessels.
1852	328.07(4)	3rd	Manufacture, exchange, or

1853			possess vessel with counterfeit or wrong ID number.
	376.302 (5)	3rd	Fraud related to reimbursement for cleanup expenses under the Inland Protection Trust Fund.
1854			
	379.2431 (1) (e) 5.	3rd	Taking, disturbing, mutilating, destroying, causing to be destroyed, transferring, selling, offering to sell, molesting, or harassing marine turtles, marine turtle eggs, or marine turtle nests in violation of the Marine Turtle Protection Act.
1855			
	379.2431 (1) (e) 6.	3rd	Soliciting to commit or conspiring to commit a violation of the Marine Turtle Protection Act.
1856			
	400.9935 (4) (a) or (b)	3rd	Operating a clinic, or offering services requiring licensure, without a license.

1857	400.9935 (4) (e)	3rd	Filing a false license application or other required information or failing to report information.
1858	440.1051 (3)	3rd	False report of workers' compensation fraud or retaliation for making such a report.
1859	501.001 (2) (b)	2nd	Tampers with a consumer product or the container using materially false/misleading information.
1860	624.401 (4) (a)	3rd	Transacting insurance without a certificate of authority.
1861	624.401 (4) (b) 1.	3rd	Transacting insurance without a certificate of authority; premium collected less than \$20,000.
1862	626.902 (1) (a) &	3rd	Representing an unauthorized

HB 183

2017

1863	(b)		insurer.
1864	697.08	3rd	Equity skimming.
1865	790.15 (3)	3rd	Person directs another to discharge firearm from a vehicle.
1866	806.10 (1)	3rd	Maliciously injure, destroy, or interfere with vehicles or equipment used in firefighting.
1867	806.10 (2)	3rd	Interferes with or assaults firefighter in performance of duty.
1868	810.09 (2) (c)	3rd	Trespass on property other than structure or conveyance armed with firearm or dangerous weapon.
1869	812.014 (2) (c) 2.	3rd	Grand theft; \$5,000 or more but less than \$10,000.
	812.0145 (2) (c)	3rd	Theft from person 65 years of

			age or older; \$300 or more but less than \$10,000.
1870	815.04 (5) (b)	2nd	Computer offense devised to defraud or obtain property.
1871	817.034 (4) (a) 3.	3rd	Engages in scheme to defraud (Florida Communications Fraud Act), property valued at less than \$20,000.
1872	817.233	3rd	Burning to defraud insurer.
1873	817.234 (8) (b) & (c)	3rd	Unlawful solicitation of persons involved in motor vehicle accidents.
1874	817.234 (11) (a)	3rd	Insurance fraud; property value less than \$20,000.
1875	817.236	3rd	Filing a false motor vehicle insurance application.
1876	817.2361	3rd	Creating, marketing, or presenting a false or

HB 183

2017

			fraudulent motor vehicle insurance card.
1877	817.413 (2)	3rd	Sale of used goods as new.
1878	817.505 (4)	3rd	Patient brokering.
1879	828.12 (2)	3rd	Tortures any animal with intent to inflict intense pain, serious physical injury, or death.
1880	831.28 (2) (a)	3rd	Counterfeiting a payment instrument with intent to defraud or possessing a counterfeit payment instrument.
1881	831.29	2nd	Possession of instruments for counterfeiting driver licenses or identification cards.
1882	838.021 (3) (b)	3rd	Threatens unlawful harm to public servant.
1883	843.19	3rd	Injure, disable, or kill police

HB 183

2017

1884			dog or horse.
	860.15 (3)	3rd	Overcharging for repairs and parts.
1885			
	870.01 (2)	3rd	Riot; inciting or encouraging.
1886			
	893.13 (1) (a) 2.	3rd	Sell, manufacture, or deliver cannabis (or other s. 893.03 (1) (c), (2) (c) 1., (2) (c) 2., (2) (c) 3., (2) (c) 5., (2) (c) 6., (2) (c) 7., (2) (c) 8., (2) (c) 9., (3), or (4) drugs).
1887			
	893.13 (1) (d) 2.	2nd	Sell, manufacture, or deliver s. 893.03 (1) (c), (2) (c) 1., (2) (c) 2., (2) (c) 3., (2) (c) 5., (2) (c) 6., (2) (c) 7., (2) (c) 8., (2) (c) 9., (3), or (4) drugs within 1,000 feet of university.
1888			
	893.13 (1) (f) 2.	2nd	Sell, manufacture, or deliver s. 893.03 (1) (c), (2) (c) 1., (2) (c) 2., (2) (c) 3., (2) (c) 5.,

			(2) (c) 6., (2) (c) 7., (2) (c) 8., (2) (c) 9., (3), or (4) drugs within 1,000 feet of public housing facility.
1889	893.13 (4) (c)	3rd	Use or hire of minor; deliver to minor other controlled substances.
1890	893.13 (6) (a)	3rd	Possession of any controlled substance other than felony possession of cannabis.
1891	893.13 (7) (a) 8.	3rd	Withhold information from practitioner regarding previous receipt of or prescription for a controlled substance.
1892	893.13 (7) (a) 9.	3rd	Obtain or attempt to obtain controlled substance by fraud, forgery, misrepresentation, etc.
1893	893.13 (7) (a) 10.	3rd	Affix false or forged label to package of controlled

1894	893.13(7)(a)11.	3rd	substance. Furnish false or fraudulent material information on any document or record required by chapter 893.
1895	893.13(8)(a)1.	3rd	Knowingly assist a patient, other person, or owner of an animal in obtaining a controlled substance through deceptive, untrue, or fraudulent representations in or related to the practitioner's practice.
1896	893.13(8)(a)2.	3rd	Employ a trick or scheme in the practitioner's practice to assist a patient, other person, or owner of an animal in obtaining a controlled substance.
1897	893.13(8)(a)3.	3rd	Knowingly write a prescription for a controlled substance for

1898			a fictitious person.
	893.13(8)(a)4.	3rd	Write a prescription for a controlled substance for a patient, other person, or an animal if the sole purpose of writing the prescription is a monetary benefit for the practitioner.
1899			
	918.13(1)(a)	3rd	Alter, destroy, or conceal investigation evidence.
1900			
	944.47 (1)(a)1. & 2.	3rd	Introduce contraband to correctional facility.
1901			
	944.47(1)(c)	2nd	Possess contraband while upon the grounds of a correctional institution.
1902			
	985.721	3rd	Escapes from a juvenile facility (secure detention or residential commitment facility).
1903			

HB 183

2017

1904	(e)	LEVEL 5	
1905			
	Florida	Felony	
	Statute	Degree	Description
1906			
	316.027 (2) (a)	3rd	Accidents involving personal injuries other than serious bodily injury, failure to stop; leaving scene.
1907			
	316.1935 (4) (a)	2nd	Aggravated fleeing or eluding.
1908			
	316.80 (2)	2nd	Unlawful conveyance of fuel; obtaining fuel fraudulently.
1909			
	322.34 (6)	3rd	Careless operation of motor vehicle with suspended license, resulting in death or serious bodily injury.
1910			
	327.30 (5)	3rd	Vessel accidents involving personal injury; leaving scene.
1911			
	379.365 (2) (c) 1.	3rd	Violation of rules relating to: willful molestation of stone

crab traps, lines, or buoys; illegal bartering, trading, or sale, conspiring or aiding in such barter, trade, or sale, or supplying, agreeing to supply, aiding in supplying, or giving away stone crab trap tags or certificates; making, altering, forging, counterfeiting, or reproducing stone crab trap tags; possession of forged, counterfeit, or imitation stone crab trap tags; and engaging in the commercial harvest of stone crabs while license is suspended or revoked.

1912

379.367(4)

3rd

Willful molestation of a commercial harvester's spiny lobster trap, line, or buoy.

1913

379.407(5)(b)3.

3rd

Possession of 100 or more undersized spiny lobsters.

1914

381.0041(11)(b)

3rd

Donate blood, plasma, or organs

1915			knowing HIV positive.
	440.10 (1) (g)	2nd	Failure to obtain workers' compensation coverage.
1916			
	440.105 (5)	2nd	Unlawful solicitation for the purpose of making workers' compensation claims.
1917			
	440.381 (2)	2nd	Submission of false, misleading, or incomplete information with the purpose of avoiding or reducing workers' compensation premiums.
1918			
	624.401 (4) (b) 2.	2nd	Transacting insurance without a certificate or authority; premium collected \$20,000 or more but less than \$100,000.
1919			
	626.902 (1) (c)	2nd	Representing an unauthorized insurer; repeat offender.
1920			
	790.01 (2)	3rd	Carrying a concealed firearm.
1921			

HB 183

2017

1922	790.162	2nd	Threat to throw or discharge destructive device.
1923	790.163 (1)	2nd	False report of bomb, explosive, weapon of mass destruction, or use of firearms in violent manner.
1924	790.221 (1)	2nd	Possession of short-barreled shotgun or machine gun.
1925	790.23	2nd	Felons in possession of firearms, ammunition, or electronic weapons or devices.
1926	796.05 (1)	2nd	Live on earnings of a prostitute; 1st offense.
1927	800.04 (6) (c)	3rd	Lewd or lascivious conduct; offender less than 18 years of age.
	800.04 (7) (b)	2nd	Lewd or lascivious exhibition; offender 18 years of age or older.

1928	806.111 (1)	3rd	Possess, manufacture, or dispense fire bomb with intent to damage any structure or property.
1929	812.0145 (2) (b)	2nd	Theft from person 65 years of age or older; \$10,000 or more but less than \$50,000.
1930	812.015 (8)	3rd	Retail theft; property stolen is valued at \$300 or more and one or more specified acts.
1931	812.019 (1)	2nd	Stolen property; dealing in or trafficking in.
1932	812.131 (2) (b)	3rd	Robbery by sudden snatching.
1933	812.16 (2)	3rd	Owning, operating, or conducting a chop shop.
1934	817.034 (4) (a) 2.	2nd	Communications fraud, value \$20,000 to \$50,000.
1935			

1936	817.234 (11) (b)	2nd	Insurance fraud; property value \$20,000 or more but less than \$100,000.
1937	817.2341 (1) , (2) (a) & (3) (a)	3rd	Filing false financial statements, making false entries of material fact or false statements regarding property values relating to the solvency of an insuring entity.
1938	817.568 (2) (b)	2nd	Fraudulent use of personal identification information; value of benefit, services received, payment avoided, or amount of injury or fraud, \$5,000 or more or use of personal identification information of 10 or more persons.
1939	817.611 (2) (a)	2nd	Traffic in or possess 5 to 14 counterfeit credit cards or related documents.

HB 183

2017

1940	817.625 (2) (b)	2nd	Second or subsequent fraudulent use of scanning device or reencoder.
1941	825.1025 (4)	3rd	Lewd or lascivious exhibition in the presence of an elderly person or disabled adult.
1942	827.071 (4)	2nd	Possess with intent to promote any photographic material, motion picture, etc., which includes sexual conduct by a child.
1943	827.071 (5)	3rd	Possess, control, or intentionally view any photographic material, motion picture, etc., which includes sexual conduct by a child.
1943	839.13 (2) (b)	2nd	Falsifying records of an individual in the care and custody of a state agency involving great bodily harm or death.

HB 183

2017

1944	843.01	3rd	Resist officer with violence to person; resist arrest with violence.
1945	847.0135 (5) (b)	2nd	Lewd or lascivious exhibition using computer; offender 18 years or older.
1946	847.0137 (2) & (3)	3rd	Transmission of pornography by electronic device or equipment.
1947	847.0138 (2) & (3)	3rd	Transmission of material harmful to minors to a minor by electronic device or equipment.
1948	874.05 (1) (b)	2nd	Encouraging or recruiting another to join a criminal gang; second or subsequent offense.
1949	874.05 (2) (a)	2nd	Encouraging or recruiting person under 13 years of age to join a criminal gang.
1950			

1951	893.13(1)(a)1.	2nd	<p>Sell, manufacture, or deliver cocaine (or other s. 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)4. drugs).</p>
1952	893.13(1)(c)2.	2nd	<p>Sell, manufacture, or deliver cannabis (or other s. 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6., (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) drugs) within 1,000 feet of a child care facility, school, or state, county, or municipal park or publicly owned recreational facility or community center.</p>
1952	893.13(1)(d)1.	1st	<p>Sell, manufacture, or deliver cocaine (or other s. 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)4. drugs) within 1,000 feet of university.</p>

1953	893.13(1)(e)2.	2nd	<p>Sell, manufacture, or deliver cannabis or other drug prohibited under s. 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6., (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) within 1,000 feet of property used for religious services or a specified business site.</p>
1954	893.13(1)(f)1.	1st	<p>Sell, manufacture, or deliver cocaine (or other s. 893.03(1)(a), (1)(b), (1)(d), or (2)(a), (2)(b), or (2)(c)4. drugs) within 1,000 feet of public housing facility.</p>
1955	893.13(4)(b)	2nd	<p>Use or hire of minor; deliver to minor other controlled substance.</p>
1956	893.1351(1)	3rd	<p>Ownership, lease, or rental for trafficking in or manufacturing</p>

of controlled substance.

1957

1958

Section 22. This act shall take effect October 1, 2017.